Microfluidic organ-on-chip for assessing the transport of therapeutic molecules and polymeric nanoconstructs by Barbato, Maria Grazia
  
 
UNIVERSITY OF GENOVA 




Microfluidic organ-on-chip for assessing the transport of 
therapeutic molecules and polymeric nanoconstructs 





Thesis submitted for the degree of Doctor of Philosophy 
XXXIII cycle   






Paolo Decuzzi Supervisor 




Francesco Gentile External examiner 
   Università degli Studi di Napoli Federico II 
Filippo Causa External examiner 
    Università degli Studi di Napoli Federico II 
 
 










Fight for things that you care about, but do it in a way that will lead others to join you. 
Ruth Bader Ginsburg 
 








I hereby declare that except where specific reference is made to the work of others, the contents of 
this dissertation are original and have not been submitted in whole or in part for consideration for 
any other degree or qualification in this, or any other university. This dissertation is my own work 
and contains nothing which is the outcome of work done in collaboration with others, except as 
specified in the text and Acknowledgements. This dissertation contains fewer than 65,000 words 
including appendices, bibliography, footnotes, tables and equations and has fewer than 150 figures. 







This Thesis would not have been possible without the costant presence of my family, Beatrice, 
Elisabetta and Gianbenedetto, and my dear Simone.  
I am deeply grateful to my supervisor Prof. Paolo Decuzzi who accompanied me into this scientific 
journey, guiding me and pushing me beyond my limits. I am taking this opportunity to thank also 
my labmates that shared with me these last years, offering always support, knowledge and 
patience. A special thanks  goes to the “little” family I met in Genova, Martina, Valentina and 
Miguel, who have been my rock in this journey. And thanks also to all the brilliant researchers 







Table of Contents 
Chapter 1 ....................................................................................................................................... 7 
State of the art ............................................................................................................................... 7 
1.1 The vascular system .............................................................................................................. 7 
1.2 Vascular Permeability ......................................................................................................... 10 
1.3 Microfluidic technologies ................................................................................................... 17 
1.4 Vasculature-on-chip ............................................................................................................ 21 
1.5 Cancer-on-chip .................................................................................................................... 26 
1.6 Brain-on-chip ...................................................................................................................... 30 
1.7 Conclusions ......................................................................................................................... 34 
Chapter 2 ..................................................................................................................................... 36 
A permeable on-Chip microvasculature for assessing the transport of macromolecules and 
polymeric nanoconstructs .......................................................................................................... 36 
2.1 Introduction ......................................................................................................................... 36 
2.2 Materials and Methods ........................................................................................................ 39 
2.2.1 Chemicals, reagents, and cells ...................................................................................... 39 
2.2.2 Microfluidic device fabrication .................................................................................... 40 
2.2.3 Extracellular matrix realization .................................................................................... 42 
2.2.4 Vascular endothelium in the microfluidic device ......................................................... 44 
2.2.5 Discoidal polymeric nanoconstructs (DPN) permeability and adhesion study ............ 46 
2.2.6 Electron Microscopy Imaging ...................................................................................... 47 
2.2.7 Cells immunofluorescence staining .............................................................................. 48 
2.2.8 Statistical analysis......................................................................................................... 48 
2.3 Results ................................................................................................................................. 49 
2.3.1 Architecture of the double-channel microfluidic device: the vascular compartment ... 49 
2.3.2 Architecture of the double-channel microfluidic device: the extravascular compartment
 ............................................................................................................................................... 52 




2.3.4 Increasing the vascular permeability to circulating agents ........................................... 59 
2.3.5 Assessing the vascular dynamics of circulating polymeric nanoconstructs ................. 64 
2.4 Discussion ........................................................................................................................... 69 
2.5 Conclusions ......................................................................................................................... 74 
Chapter 3 ..................................................................................................................................... 76 
Efficacy of molecular and nano-therapies on brain tumor models in compartmentalized 
microfluidic devices .................................................................................................................... 76 
3.1 Introduction ......................................................................................................................... 76 
3.2 Materials and Methods ........................................................................................................ 79 
3.2.1 Fabrication and Characterization of the Microfluidic Chips ........................................ 79 
3.2.2 Scanning Electron Microscopy (SEM) ......................................................................... 80 
3.2.3 Culture of Human Glioblastoma Multiforme (U87-MG) Cells and Primary Human 
Astrocytes .............................................................................................................................. 81 
3.2.4 Human Glioblastoma Multiforme (U87-MG) Cells in static culture conditions .......... 81 
3.2.5 Treatment Conditions using Single and Double Channel Microfluidic Chips ............. 82 
3.2.6 Confocal Microscopy Analysis .................................................................................... 83 
3.2.7 Statistical Analysis ....................................................................................................... 84 
3.3 Results ................................................................................................................................. 85 
3.3.1 Assessing the cytotoxic potential of therapeutic agents in the single-channel 
microfluidic device ................................................................................................................ 88 
3.3.2 Assessing the cytotoxic potential of therapeutic agents in a double-channel 
microfluidic device ................................................................................................................ 91 
3.4 Discussion and Conclusions ................................................................................................ 98 
Chapter 4 ................................................................................................................................... 102 
Three-dimensional extracellular layer mediated neural stem cell differentiation in a 
microfluidic device .................................................................................................................... 102 
Chapter 5 ................................................................................................................................... 108 
Conclusion and Future Perspectives ....................................................................................... 108 
List of publications ..................................................................................................................... 112 







 State of the art 
 
1.1 The vascular system 
The discovery of the circulatory system represented a revolution that completely changed the 
understanding of living systems. The first description of the circulatory system dates back to 1628 
when William Harvey demonstrated that blood circulated  around the body through a system of 
arteries and veins. In 1865, Wilhelm His coined the term “endothelium” to differentiate the inner 
lining of body cavities from “epithelium”. Few years later, in 1874, Theodor Schwann observed, 
for the first time, the capillary wall in tadpole. [1] The branched network of blood vessels, 
consisting of arteries, veins, and capillaries, ensures tissue and organ homeostasis, delivery of 
gases, nutrients, metabolites,  cells, and removal of waste products. These functions are developed 
earlier in the embryo, where spatio-temporally defined interactions lead to establishing a functional 
vascular system. [2] During development, vasculature develops through vasculogenesis, the 
formation of de novo vessels from the association of endothelial cell precursors known as 
angioblasts, and angiogenesis, the formation of new vessels by sprouting of pre-existing vessels 
(Figure 1.1). Formation of vasculature is followed by stabilization, involving the recruitment of 




coming from the environment and lastly specialization, including arterio-venous determination 
and organ-specific capillary structure. [3] 
 
 
Despite regional and organ differences, blood vessels consist of three distinct regions: 
 Tunica intima, a single layer of endothelial cells, lying on the basal lamina; 
Adapted from Jain, R.K., Nature medicine, 2003. 
Figure 1.1. Formation and maturation of vascular network. Vasculature forms via 
vasculogenesis or angiogenesis, processes regulated by cell-cell and cell-matrix interactions. 
The nascent vasculature undergoes further steps of stabilization, branching and remodeling. 
During last step of specialization, a stable network of arteries, veins and capillaries is 




 Tunica media, containing smooth muscle cells (SMCs) and elastic fibers: 
 Tunica adventitia, composed of fibro-elastic connective tissue. [4] 
Based on the type of vessels and organs in which they reside, endothelial cells (ECs) show defined 
structural  and functional properties. Organ-specific vasculature differs in permeability, delivery 
of nutrients to organs and traffic regulation of immune cells. [5]  
Adapted from Potente et al., Nature Reviews Molecular Cell Biology, 2017 
Figure 1.2. Schematic of vascular organization. Arteries (red), veins (blue) and 
interconnected capillaries constitute the vascular network. Arterioles, capillaries and venules 
constitute the microvasculature. Three type of capillaries can be found: continuous, fenestrated 




Capillaries constitute  the majority of surface area of circulation, resulting in ~ 4000-7000 m2 for 
an average-sized human. [6] Across this surface, nutrients, solutes, and water are exchanged 
between blood and tissues through diffusion and convection. A single layer of endothelial cells, 
lying on the basal lamina surrounded by pericytes, constitutes the capillary network leading to 
small vessels with a diameter of 5-10 µm. There are three types of capillaries: continuous, 
fenestrated, and sinusoidal (Figure 1.2).  
Endothelial cells of continuous capillaries, for instance, brain capillary, are tightly bound together, 
allowing the passage of water, small molecules, and lipid-soluble materials while restricting the 
diffusion of larger molecules, drugs, and pathogens. Fenestrated capillaries, observed, in kidneys 
and some intestinal tracts, present pores that enable the passage of larger solutes that are 
compatible in size with peptides. Sinusoidal capillaries, located in the liver and spleen, present 
gaps between endothelial cells allowing the passage of larger molecules comparable in size with 
plasma proteins. [7] 
 
1.2 Vascular Permeability 
The term “closed” commonly describes the vascular system, but physiologically it also needs to 
be “open”, meaning permeable, to ensure the exchange of gases, nutrients, and wastes across 
tissues. Leakage of a dye from the capillaries of a developing amphibian tail was first observed in 
1935, describing the phenomenon of vascular permeability for the first time. [8] Vascular 
permeability is an intrinsic feature of blood vessels, reflecting the integrity and tightness of the 




to physiological and biological needs (for example, temperature, exercise), and contributes to the 
pathophysiology of many diseases, such as arthritis, infections, stroke, and cancer. [9] Along the 
vascular tree, arterioles present low permeability values, while venules present higher permeability 
values, from ~10-6 to 10-4 cm/s.[10] Capillaries and post-capillary venules are considered as the 
site of fluids, solutes, and nutrients exchange. Capillaries are responsible for fluid passage, while 
post-capillary venules are mainly responsible for plasma proteins leakage and leucocyte 
extravasation. [11]  
Two different pathways contribute to the movement of solutes across the endothelial barrier 
(Figure 1.3): 
Adapted from Park-Windhol et al., Annu.Rev.Pathol.Mech.Dis, 2016 
Figure 1.3. Paracellular and Transcellular pathways across endothelial cells. The transport of fluids and 




 The paracellular route, enabling free convective and diffusion transport of molecules and 
solutes smaller than 3-5nm through the opening and closing of adherens junctions (AJs) 
and tight junctions (TJs): 
 The transcellular route or transendothelial vesicular transport, passing  through a vesicles-
mediated transport of molecules and involving caveolae and vesiculo-vacuolar organelles. 
[12] 
Adjacent endothelial cells are connected by AJs and TJs, whose number and organization are 
organ- and tissue-specific. Two cadherins are highly expressed by endothelial cells : VE-cadherin, 
which is specifically presents on endothelial cells, and neuronal cadherin (N-cadherin), which is 
presents also on neural cells and smooth muscle cells. Despite similar level of protein expression 
only VE-cadherin is located at cell–cell contacts, whereas N-cadherin is distributed over the whole 
cell membrane [13, 14] VE-cadherin junctional protein is essential for endothelial barrier integrity 
and it is characterized by  extracellular cadherin motifs, a transmembrane domain and an 
intracellular domain. The juxtamembrane intracellular domain mediates the interaction with p120, 
while the distal intracellular domain interacts with β-catenin and plakoglobin, which bind in turns 
to α-catenin, linking the VE-cadherin complex to the actin cytoskeleton. [9, 13] Three families of 
transmembrane proteins compose the TJs: claudins, occludins and junctional adhesion molecules 
(JAMs). Through their cytoplasmatic domain, these proteins are linked to the actin cytoskeleton 
via binding proteins like ZO-1 and cingulin, thus directing, controlling and limiting paracellular 
permeability. AJs are necessary for the formation of TJs, leading to the concept that changes in 




An increase in endothelial permeability is related to the formation of small gaps between 
endothelial cells, and change in VE-Cadherin distribution along cell borders. Hyperpermeability 
conditions are linked to an increase in endothelial permeability, can be brief and reversible after a 
stimulus such as acute inflammation, or sustained  as in chronic inflammation and tumors (Figure 
1.4). [9, 13] 
 In particular, besides epigenetic and genetic changes, tumors require the induction of a tumor 
vasculature. Neo-vascularization in tumors is a key step to ensure the supply of oxygen, 
metabolites, and waste removal for tumor progression. Tumor blood vessels are irregular and 
Adapted from Claesson-Welsh et al., Cell Press, 2020 
Figure 1.4. Dynamics of vascular permeability. In normal vessels, cells are arranged into a uniform barrier that 
prevents the leakage of proteins and solutes. In acute inflammation, gaps formed between endothelial cells, leading to 
a transient increase in endothelial permeability. In chronic inflammation, a sustained increase in permeability in 
associated with gaps formation that can be reverted only with pharmacological treatments. In cancer, the formation of 




tortuous, and blood flow is slow and irregular. They are often leaky and hemorrhagic, resulting in 
an upregulated inflammatory response. [16]  
Permeability-increasing agents or endothelial barrier protectors modulate endothelial 
permeability. Among permeability-increasing agents, vascular permeability growth factor 
(VEGF), discovered in 1980s, is the most well-known. Activation of VEGF leads to the 
phosphorylation and disassembly of VE-cadherin, promoting formation of gaps and plasma 
leakage. [17] Similarly, thrombin, histamine, bradykinin, nitric oxide (NO), and 
lipopolysaccharide (LPS) promote vascular permeability. [9, 12] Conversely, endothelial barrier 
protectors, like cyclin-adenosine-monophosphate (cAMP), Sphingosine-1 (SP1), and 
Angiopoietin-1 (Ang-1), prevents increases in endothelial permeability, thereby preserving the 
endothelial barrier integrity.  [12, 17] 
Permeability coefficients represent the functional measure of microvascular exchanges of capillary 
walls. The exchange of fluids across the endothelium is driven by the difference in hydrostatic 
pressure generated by the circulating blood fluid and the concentration gradients of plasma proteins 
between the vascular lumen and the extravascular space. [11]  This is expressed in the Starling 
equation, summarized as: 
𝐽𝑣 𝐴 =  𝐿𝑝 ⁄ [∆𝑃 − 𝜎∆𝜋] (Eq.1) 
Where Jv is the fluid volume filtration rate (mL/s); A is the endothelial surface area (cm2); ΔP is 
the hydrostatic pressure difference across the capillary wall (mmHg); Δπ is the oncotic pressure 
difference, derived by plasma proteins between the lumen and extravascular compartment. In 




to water; σ is the osmotic reflection coefficient, that describes the sieving properties of capillaries 
(comprise between 0 and 1, where 0 define a completely permeable capillary, and 1 a completely 
impermeable capillary). [18] Under physiological conditions, there is no plasma protein crossing 
into the interstitial tissue (concentration of albumin in the blood is 4.5 g/dL). Consequently, the 
oncotic pressure is directed into tissue, while the hydrostatic pressure is directed into the lumen of 
the vessel. In pathophysiological conditions, plasma proteins accumulate into the tissue, leading 
to the accumulation of large quantities of fluid and leads to edema formation. [11] The exchange 
of solutes across the capillary walls is related to two forces, convection and diffusion. When 
plasma proteins are dragged along the fluid current, convection prevails as exchange mechanism; 
instead, when the fluid becomes slow in distal microvessels, diffusion prevails. In this condition, 
it is the Fick’s law that describes the passive diffusion of solutes with the following equation: 
𝐽𝑠 = 𝐷 ∗ 𝐴 ∗  ∆𝐶 ∆𝑥⁄  (Eq.2) 
Where, Js is the flux of solute, driven by a concentration difference (ΔC) over a surface area A, 
along the distance Δx, following the diffusion coefficient D of the solute. [19]  
Diverse approaches, both in vitro and in vivo, are used to measure endothelial permeability 
quantitatively. Generally, in vitro, endothelial cells are cultured as a monolayer on porous filters 
in Transwell chambers to ensure the endothelial barrier tightness. Through fluorescent-based 
approaches, the accumulation of a fluorescent tracer from the top compartment to the bottom 
compartment is measured as a function of relative fluorescence intensity over time. [17] 
Alternatively, it is possible to measure endothelial barrier integrity as a function of the electrical 
resistance. Lipophilic molecules cover endothelial cells' membranes, restricting the passage of 




(TEER) is a function of the electrical resistance of the endothelium.  Probes are placed in the 
luminal and abluminal side, and the impedance to flow to small inorganic ions is calculated, 
reflecting the barrier integrity of the endothelial monolayer. [11] However, in vitro, most common 
endothelial cells used in culture are derived from large vessels that cannot be representative of 
microvascular cells. Usually, endothelial cells  cultured on a plastic substrate undergo significant 
changes in phenotype and upregulation of  inflammatory genes. Moreover, loss or alterations of 
adhesion and junctional proteins lead to higher permeability values. Simultaneously, lack of flow 
conditions, basement membrane and supporting cells do not resemble the blood vessel 
physiological structure. [20] In vivo approaches for the measurement of vessel permeability rely 
on cannulation and perfusion of single vessels in selected region of the microvascular bed. The 
most commonly used assay is the Mile Assay.[21] In this technique, a colored dye, that strongly 
bind to albumin (e.g. Evans blue), is injected into blood circulation, and its accumulation into a 
specific site is observed over time. However, this technique present several limitations. For 
example, it is not compatible with non-inflamed tissue, where albumin does not cross the 
endothelium. Dual Isotope approach, Intravital Microscopy, Magnetic Resonance Imaging (MRI) 
and Positron emission tomography (PET) techniques are also employed to measure endothelial 
permeability in vivo. [11, 17] However, animal experiments are time-consuming, technically 
demanding, suffer from intrinsic variability between animals and present well-known ethical 
limitations. More importantly, several legislation require adherence to the 3R principles (replacing, 
reducing and refining) to reduce animal testing while promoting alternatives. In this scenario, 
microfluidic technologies offer the possibility to overcome the limitations of in vitro approaches 
in vascular biology, and at the same time to faithfully recapitulate the in vivo physiological 




1.3 Microfluidic technologies 
By definition, microfluidic is the manipulation of small amounts of fluids (10-9 to 10-8 liters) using 
channels of width ranging from tens to hundreds of micrometers. [22] By employing technologies 
first developed in the semiconductor industry, fluids can be manipulated using microscale devices. 
In 1950s, the first microfluidic technology was developed, putting the efforts for dispensing small 
amounts of fluids in the range of nano- and picoliter – the basis of the actual ink-technology. Years 
later, a simple microfluidic analysis system based on capillary liquid structure reached the market. 
These systems were used  in the detection of pregnancy, drug abuse, or cardiac markers. [23] In 
the recent years these microfluidic devices are referred as “lab-on-chip”. They have also been 
applied in the biological research, offering several advantages: the reduction of volumes and 
reagents cost, the spatio-temporal control of cell environment and the possibility of assay 
parallelization. At the microscale, fluid phenomena are different from those that are dominant  at 
the macroscale. In particular, laminar flow, surface tension and capillaries forces are the ones that 
dominate at the microscale level, which translate into phenomena like passive pumping into 
microchannels, precise surface patternig and monodisperse droplets formation. [24] 
Primarily, the development of microfluidic devices focused on the fabrication of silicon and glass, 
using cleanroom techniques. For the selection of substrate materials for a microfluidic device in 
biological research, it is important to consider some particular characteristics such as optical 
transparency for cell imaging, the desired degree of mechanical rigidity or flexibility, surface 
chemistry reactivity and biocompatibility. According to these criteria, it is clear that both silicon 




 Silicon is opaque to visible and ultraviolet light, making it incompatible with microscopy 
techniques and requires expensive fabrication techniques; 
 Glass is a brittle material, requires non trivial-bonding process, and possesses inaccessible 
and expensive fabrication methods. [25] 
In the 1970s, the Bell Lab developed a new fabrication technique, the elastomeric micro-
molding.[26] In 1998 the first PolyDiMethylSiloxane (PDMS) microfluidic device was fabricated 
by the group of Whitesides, giving rise to the era of soft-lithography. [27] PDMS in an optically 
transparent elastomer, that is permeable to gas and vapor. It is widely adopted in bio-microfluidic 
applications due to its  relatively low-cost, ability to tune its hydrophobic-hydrophilic properties, 
reversible and irreversible bonding to glass and other materials and its elasticity. [24, 25] There is 
a wide range of microfabrication techniques for producing microfluidic devices. The most 
commonly used fabrication process is photolithography, a set of techniques initially developed by 
the semiconductor industry. Photolithography involves the use of a photosensitive polymer, so-
called photoresist, to pattern the microfluidic structure. Two types of photoresist exists, positive 
and negative . When a positive photoresist is exposed to UV light, the exposed region becomes 
soluble and the unexposed region is polymerized. In the case of negative photoresist, the opposite 
occurs, the exposed region becomes polymerized, and the unexposed area is soluble in an 
appropriate solution. During the photolithography process, a layer of resist, generally SU-8, a 
commonly used epoxy-based negative photoresist, is spin-coated onto a substrate, silicon, or glass 
wafer. Then, it is structured with a photomask, creating the targeted channel layout.  After 
patterning, the un-polymerized photoresist is removed by rinsing with an appropriate solvent, 
leaving the microfluidic design patterned on the wafer. Subsequently, the glass or silicon can be 




to form the structures in the substrate. [28] But, as previously reported, silicon and glass are not 
suitable materials for biological applications. 
The most widely used approach to fabricate microfluidic devices is soft-lithography. The success 
of the technique is related to its  simplicity, the materials properties, its relative low cost, the 
advantageous surface chemistry and replication accuracy. In this process, instead of using the 
wafer material to fabricate the chip, the wafer is now used as a mold with a positive channel 
structure relief. A thermosetting elastomer is poured over the mold and allowed to polymerize, 
reproducing the microfluidic layout (Figure 1.5). 
The most used material in microfluidic devices is PDMS. Typically, ten parts of the elastomer and 
one of the curing agents are mixed together, forming three-dimensional bonds through an 
organometallic crosslinking reaction.[29]  The mixture is then degassed, poured over the master 
template, and cured at room temperature for at least 48h. Using higher temperatures  reduced the 
Adapted from Beker et al., Anal Bioanal Chem, 2008 
Figure 1.5. Creation of microfluidic devices. A soft-lithography approach is used 
to create the microfluidic pattern. PDMS is poured over the master template 
generating a stamp. The stamp can be irreversibly bonded to a basement substrate 




curing time. After polymerization, the elastomer with embedded structure is peeled off the wafer, 
building three-dimensional structures that can be closed by placing another piece of elastomer or 
glass via bonding procedures. [25, 28]  
In biological research, animal studies remain the gold standard for the preclinical validation of 
drugs in pharmaceutical development. However, besides the well-known ethical limitations, 
several studies from the Food and Drugs Administration (FDA) and the National Institute of Health 
(NIH) revealed a failure of ~90% in the results of drug testing from animal models. [30] On the 
other hand, in vitro cell cultures lack the in vivo tissue architecture, physiological functions, 
complex tissue and organ-level structure, and the interplay between multiple organs.  As 
alternative models to animal studies, organoids have been proposed. However, these 3D models 
Adapted from Ma et al ,Trends in Pharmacological Sciences, 2021 
Figure 1.6. Microfluidic technologies. Organ-on-chips bridge the gap between in 
vitro (2D and 3D) and in vivo conditions giving the possibility of mimic 




lack tissue-tissue interfaces, vascular flow, and mechanical cues. Thus, to bridge the gap between 
in vivo and in vitro conditions, starting from the early 2000s, microfluidic technologies have been 
applied (Figure 1.6). [31, 32] 
Microfluidic Organ-on-Chip can recapitulate vascular perfusion, tissue-tissue and tissue-matrix 
interactions aiming to reproduce organotypic cellular microenvironment and functionality for 
disease modeling and drug screening.[33] These can be lined with most of the cell sources 
available, such as primary cells, induced pluripotent stem cells (iPSC), or cells derived from 
patients for personalized medicine. In the last years, several microfluidic models have been 
proposed in order to recapitulate human physiological features, disease state and drug screening. 
[34] Single Organ-on-Chip recapitulate a specific tissue or organs, but it is also possible to 
fluidically link multi organ-on-chip in order to model the so-called “Body-on-chip”. These 
platforms showed better response than animal models as drug screening platforms for 
pharmacokinetics and pharmacodynamics study, giving evidence that microfluidic patforms can 
be employed as potential alternative to animal models. [35]   
 
1.4 Vasculature-on-chip 
From an engineered point of view, the human vascular tree ranges from the centimeter-scale aorta 
to micrometer-scale capillaries. To engineer the complex capillary network and endothelial barrier 
functions, numerous strategies have been developed to capture the complexity of the vascular 
niche.   Over the past decades, tissue-engineers fabricated large vessels ranging from 1 to 10 mm 




when it comes to microvascular networks, design and fabrication techniques employing 
lithography, 3D printing and laser ablation techniques need to be revised. Microvasculature is 
structured as a dense network of micro-sized capillaries (~5-10 µm) located <100 µm from one  
another. [36] It was the 1980, when Judah Folkman and Christian Haudenschild observed for the 
first time the formation of vascular lumen in vitro. In the assay, endothelial cells (ECs) formed 
tubes onto an extracellular matrix (ECM) by using collagen, fibrin or Matrigel. [37] Years later, 
development of microfluidic systems offered the possibility of integrating angiogenesis-on-chip 
introducing additional stimuli as flow, biochemical gradients, and compartmentalized co-culture. 
Based on fabrication methods, microfluidic vessels can be divided into three main categories: 
1. 2D layer of endothelium in microfluidic model; 
2. 3D lumenized microvasculature adopting the wall patterning method; 
3. 3D lumenized microvasculature based on self-morphogenesis. 
The first two categories are based on  top-down fabrication approach, while a bottom-up 




In 2D layer of the endothelium in microfluidic devices, ECs are attached to the microfluidic 
channels' walls. Though ECs are not directly cultured into a 3D matrix, they gained specialized 
features from contact with the ECM, from a co-culture with parenchymal cells that can be loaded 
into a parallel channel, or from the flow.  Another significant advantage of this type of 
Figure 1.7. Vessel-on-chip main categories. A). 2D layer of endothelium in microfluidic device. 
B)  3D lumenized microvasculature based on the wall patterning method. C) 3D lumenized 




configuration is the possibility of measuring the permeability of the vessel. In this context, 
Kamm’s group gave a masterful example. They developed a microfluidic vascular-tumor interface 
for precise quantification of endothelial barrier function. Endothelial permeability was measured 
across HUVEC monolayer in the presence or absence of tumor cells, and tumor cell migration was 
calculated under control and inflammatory conditions. [39] A drawback of this technique is the 
non-physiological rectangular shape of the channels. 
 
To address this issue, 3D lumenized microvasculature can be generated by sacrificial molding or 
wall patterning method. In this approach, particular attention is given to reconstituting 
microvessels in a 3D structure. A hollow capillary network in 3D ECM can be generated 
employing different techniques. One of the earliest techniques developed was needle molding. 
Tien group in 2006 was a pioneer in developing perfusable vessel structures by casting a hydrogel 
around a removable needle. Upon removing the needle, ECs were introduced into the channel and 
allowed to adhere to the hydrogel walls. [40] A different technique to model complex 3D 
vasculature is by sacrificial molding. A sacrificial material is cast into molds to form the desired 
layout. Subsequently, the material is embedded within a hydrogel and, after its solidification, the 
sacrificial material is washed away, leaving behind the desired structure. Kaplan group combined 
gelatin sacrificial molding and a layer-by-layer approach to fabricate a silk hydrogel microfluidic 
system. Briefly, a negative PDMS stamp was used to form a positive gelatin microchannel that 
was subsequently transferred into the silk hydrogel solution. This step was repeated two times in 
order to form a complex 3D structure layer-by-layer. After the assembly, the gelatin mold was 




have been directly generated in hydrogels by photoablation or photodegradation. Lasers with 
enough energy to break down covalent bonds can ablate microscale voids in various soft hydrogels, 
such as collagen, fibrinogen, and silk protein hydrogel. [42] The Slater group generated a complex, 
dense and tortuous vascular network by laser-based degradation and image-guided laser control 
onto a poly-(ethylene glycol) diacrylate (PEGDA) hydrogel recapitulating accurately the in vivo 
microvasculature. [43] Because of the broad application potentials, 3D printing has gained great 
attention in the last decades. 3D printing techniques can be divided in two main categories: 
directing printing, where a cell-laden material is deposited onto a surface, and indirect printing, 
where a sacrificial material is embedded into a large cell-laden material. [36] Dvir group reported 
a 3D-print thick, vascularized and perfusable cardiac tissue. [44] Starting from a biopsy of omental 
tissue, a patient-specific extracellular matrix was developed as bio-ink. Cells, derived from the 
same biopsy tissue, were reprogrammed into pluripotent stem cells, and differentiated to 
cardiomyocytes and endothelial cells. Subsequently, the two cell types were combined with the 
bio-ink to print the parenchymal cardiac tissue and blood vessels. [44]  
Vascular networks can also be formed by a bottom-up approach as in 3D lumenized 
microvasculature based on the self-morphogenesis. Instead of seeding cells into predefined 
structures, ECs can exploit angiogenesis and vasculogenesis processes to generate functional and 
stable microvascular structures. By balancing angiogenic factors and a suitable ECM, 3D 
microvasculatures are assembled into microfluidic devices. Kamm group generated a 3D 
microvascular network into a fibrin extracellular matrix by co-culturing endothelial cells and 
stromal cells. The designed microenvironment favored vasculogenesis, by forming endothelial 
connections, branch and anastomosis, resembling the in vivo vasculature. Moreover, the 3D 




glycocalyx, and size and  charge-selective barrier to the passage of solutes. [45] Recently, 3D-self 
assembled microfluidic vasculature has been applied to overcome one of the major limitation of 
organoids and spheroids, meaning, the development of a functional and perfusable vasculature. 
[46] Recently, it was reported a spheroid model containing a perfusable vascular network by 
defining the cellular interaction between the spheroid and endothelial cells [23]. Yokokawa group 
developed a tumor spheroid with an integrated perfusable vascular network to recapitulate the in 
vivo tumor microenvironment. Tumor spheroids were perfused over 24h through the vascular 
network, and anti-cancer drug assays were performed. [47]  
A plethora of perfusable microvessel models have been developed. They can be classified based 
on the fabrication method used in 2D layer of the endothelium in a microfluidic model, 3D 
lumenized microvasculature by wall patterning method and 3D lumenized microvasculature by 
self-morphogenesis. Microfluidic vessels vary in complexity and physiological relevance, but 




As reported by the International Agency for Research on Cancer (IARC), cancer is the second 
leading cause of death globally, accounting for an estimated 9.6 million deaths in 2018. [48] 
Testing potential anticancer drugs in tumor cell cultures is the first step in cancer therapeutics 
preclinical development. Subsequently, animal models are necessary to proceed into preclinical 




xenograft could be implanted into the same organ from which the tumor is derived, obtaining an 
orthotopic cancer model. However, both cell culture models and animal studies do not replicate 
the complex tumor microenvironment (TME), resulting in poor or altered therapeutic treatment 
response. [49] To bridge the gap between 2D in vitro cell culture and animal models, a new class 
of in vitro tools came into the arena. Integration of organotypic tumor cell culture with microfluidic 
devices, so-called “cancer-on-chip,” allowed the recreation of TME. This allows  researchers to 
understand tumor cell behaviors, investigate cancer cell interactions with other organs and spatio-
temporal dynamics of tumor cascade. [50] Researchers for over 50 years used 2D cell cultures to 
assess the effect of drugs on tumor growth.  
Adapted from Sontheimer- Phelps et al., nature Reviews Cancer, 2019 
Figure 1.8. Timeline of cancer-on-chip development. Steps of tumor cascade replicated into microfluidic 




Over the past years,more complex systems have been developed in the Transwell system using 
tumor spheroids, aggregates of cells cultured in non-adherent conditions, to replicate a 3D tumor 
model. However, these models failed to recapitulate essential mechanical cues: shear stress, 
hydrostatic pressure, and tissue deformation. Microfluidic cancer-on-chips offer the possibility of 
integrating multicellular tissue-tissue interfaces, relevant microenvironment, perfusion and  
controlled biophysical, cellular and molecular stimuli. Cancer-on-chips offer the advantage of 
replicating specific step of the tumor cascade, as tumor growth and expansion, invasion and 
metastasis (Figure 1.8). [51]  
Takayama group demonstrated the effective formation of tumor spheroids in microfluidic devices, 
recapitulating the niche microenvironment of prostate cancer metastases into the bone. They 
engineered a two-layer microfluidic system including prostate cancer cells, osteoblasts and 
endothelial cells. The fabricated micro-trap ensured the uniform incorporation of all cell types into 
the spheroid that was kept in place over one week. The culture system faithfully recapitulated the 
in vivo growth of cancer cells within the bone metastatic prostate cancer microenvironment. [52] 
Interaction between tumor cells and its microenvironment is a key regulator of tumor progression, 
particularly in the formation of a premetastatic niche. For integrating tissue-specific cell cultures, 
microfluidic devices are a powerful platform for recapitulating the complicated metastatic tumor 
cascade. Kamm group presented a microfluidic platform in which they combined a microvascular 
network assembled via vasculogenesis, different cancer cell lines and a highly controlled 
microenvironment. They assessed the extravasation of cancer cells from the microvascular 
network in real-time, gaining insights into tumor cell extravasation mechanisms. [53] More 




investigate the mechanism of tumor cell homing, colonization, and proliferation in distant organs. 
[54] Interactions of cancer cells with microenvironment are extremely important to evaluate the 
effectiveness of anti-cancer drugs. Still, it is also important to assess the side effects of anti-cancer 
drugs on other organs. In fact, many drugs that pass preclinical tests are often withdrawn due to 
side effects detected during clinical trials or even after entering the market.  Vunjak-Novakovic’s 
group developed a multi-organ-on-chip platform by integrating two bioengineered human tissues, 
a bone tumor tissue and heart muscle, in order to evaluate the anti-tumor efficacy and 
cardiotoxicity of linsitinib. This anti-cancer drug showed promising results in patient-derived 
orthotopic xenograft models but failed in clinical trial Phase II. Their results showed that only 
engineered tumor tissues recapitulating bone microenvironment and integrated with heart muscle 
tissue were comparable with results from clinical trials, demonstrating that multi organ-on-chip 
could improve the predictive accuracy for direct and off-target effects of drugs. [55] For 
personalized anti-cancer treatments, patient-derived cancer cells have been analyzed in 
microfluidic models. The Wang group realized a 3D co-culture platform to evaluate drug 
sensitivity for a mono-lung cancer cell line, a mixture of lung cancer and stromal cell lines, and 
cells freshly derived from lung cancer tissues. In the co-culture condition, stromal cells and cancer 
cells gradually clustered to form a 3D spheroid, recreating a well-organized in vivo-like 
microenviroment. Moreover, the apoptosis rate of lung cancer cells decreased around two times 
when co-cultured with stromal cells, compared to mono-culture cells. In order to provide effective 
clinical guidance for individualized treatment, the anti-cancer drug sensitivity tests were carried 
out on fresh tissues of cancer. They defined the appropriate chemotherapeutic scheme for eight 





Overall, organ- and cancer-on-chip could provide more significant insights into anti-cancer drug 
screening and toxicity before entering clinical trials. Cancer-on-chip can be linked with different 
physiological compartments, helping to predict drug side effects on different organs like the heart, 
liver and kidneys. Moreover, personalized cancer-on-chip could elevate personalized medicine to 
higher level, by recapitulating patient-specific pathophysiology and therapy response.  
  
1.6 Brain-on-chip 
In the central nervous system (CNS), the brain is the central player. Composed by 100 billion of 
neurons and 1 trillion  of supporting glial cells finely arranged from the molecular to the organ 
level, the brain orchestrates and regulates the functions and mechanisms of the CNS in a delicate 
balance between the delivery of nutrients and energy supply for neuronal activity. [57] 
Neurophysiology and neuropathology studies are based on various model organisms, such as 
Caenorhabditis elegans (C.elegans), Drosophila, rodents and non-human primates. The models 
offer advanced  understanding of the brain and brain-related disorder pathophysiology, but critical 
issues remain. For example, manipulating small organisms such as C.elegans and Drosophila 
requires a certain level of expertise and is labor-intensive. On the other hand, rodent and non-
human primates, despite significant similarities with humans, fail to recapitulate the essential 
features of the brain. [58] Together with animal models, 2D neural cell cultures are model systems 





Adapted from Zhao et al., Lab on Chip, 2020 
Figure 1.9. Microfluidic chip for neurobiology. (A) Microfluidic applied at the molecular level to direct 
neural differentiation, generate neurochemical gradients and neurotransmitter profiles. B) Microfluidic 
applied at the cellular level to study neural and non-neural cell crosstalk and neuro-guide formation. C) 
Microfluidic applied at the tissue level to recapitulate blood-brain-barrier (BBB) model and 




Advances in 3D culture and neural differentiation led to new relevant models as 3D-scaffold neural 
structures, neuro-spheres and cerebral organoids. However, self-assembly of organoids and neuro-
spheres does not resemble the exact position of neural cells. There is limited control of the 3D 
microenvironment in terms of neurochemical signals, neural cell type and ECM. [59] The coming 
era of microfluidic technologies offered the possibility of developing new neuro-microfluidic 
platforms to accommodate sophisticated mechanisms of neural cell cultures and controlled 
microenvironments. Brain-on-chip can (i) mimic the spatio-temporal dynamics of neurochemical 
signals; (ii) facilitate single neuron analysis and multi-cellular interactions; (iii) emulate 
neurophysiological and neuropathological conditions, accelerating the research and development 
of therapies for brain-related diseases such as Parkinson’s, Alzheimer and brain tumors (Figure 
1.9). [60] 
Microfluidic chips at the molecular level provided a fine-tuned technology for generating gradient 
concentration of neurochemical molecules and determining neural fate. It is also possible to 
integrate into microfluidic devices opto- and electrochemical sensors coupled with real-time 
monitoring and analysis equipment. Lu and co-workers developed a microfluidic platform to 
culture stem cell aggregates under differently  perturbed flow conditions. Particularly, they focused 
on the effect of device geometry and media exchange frequency. Discontinuous perfusion 
demonstrated optimal growth of stem cell aggregates and modulation of the device geometry-
generated gradients of cell-secreted factors reflected in spatial differentiation patterns. [61] 
Microfluidic devices can modulate neural activities and functions by fine-tuning cellular 
interactions and the surrounding microenvironment at the cellular level. Volontè’s group studied 




Micropillar-shaped geometry, micropatterned line-grating geometries and microfluidic channels 
were fabricated. They showed that primary microglia tended to be multipolar, extending 
protrusions in all directions and forming distinct pseudopodia on pillar-shaped geometries. 
Conversely, on both line-grating geometries and microfluidic channels, microglia presented a 
stretched and flattened morphology, assuming a filopodia-bearing bipolar structure. [62] 
At the tissue level, microfluidic setup recapitulated key features of neurophysiological and 
neuropathological conditions, as Alzheimer's disease (AD), [63] Parkinson's disease (PD), [64] 
and amyotrophic lateral sclerosis (ALS).[65] Significant efforts have been made to recapitulate the 
blood-brain-barrier (BBB) on-chip and accelerate the development of new therapeutic strategies 
for brain-related disorders. Ingber group reported the development of a BBB organ-on-chip formed 
by induced pluripotent stem cell (iPSC)-derived human brain microvascular cells, primary human 
brain astrocytes and pericytes. To obtain highly differentiated and stabilized brain microvascular 
endothelial cells, iPSCs were cultured in hypoxic-condition, producing significant increases in the 
mRNA levels for the endothelial cell-to-cell adhesion molecules, VE-cadherin (vascular 
endothelial cadherin) and PECAM-1 (platelet endothelial cell adhesion molecule, also known as 
CD31), as well as the influx transporter GLUT-1 (BBB-specific glucose transporter), efflux 
transporter P-gp (permeability glycoprotein), and VEGF-A (angiogenic vascular endothelial 
growth factor-A), relative to control under normoxic conditions.   The developed BBB-on-chip 
demonstrated low barrier permeability values similar to those observed in human brain for more 
than 2 weeks in vitro, reversible opening of the BBB using hypertonic mannitol solutions in vitro, 
as is done in vivo. The delivery of an FDA approved therapeutic antibody, mimicking a clinically 




substrate specificity was achieved. These results provide significant advancement in drug 
screening applications. [66] 
Microfluidic brain-on-chip offers great opportunities for neuroscience research and for 
personalized treatments of brain diseases. These neurological platforms could help discover the 
contributions of different cells and cytokines to neuropathological disorders and how cues in 
neuronal microenvironment regulate cell differentiation, neuronal development and progression of 
neurological disorders.  
 
1.7 Conclusions 
Microfluidic systems provide the technology to develop in vivo-like environments for the study of 
a broad variety of physiological and pathophysiological models. Integration of 3D extracellular 
matrix into microfluidic channels gives the opportunity to move from 2D culture models to 3D 
and multi-organ systems. Vasculature-on-chips represent a powerful tool for fundamental research 
into angiogenesis as well as vasculogenesis.  Specifically, formation of functional vascular systems 
offer the possibility of screening biomolecules, drugs and nanoparticles in drug delivery 
application. In addition, cell motility and movement across vascular barriers are of great interest, 
in particular for research into metastasis. In cancer biology, organ-on-chips have resulted in highly 
complex three-dimensional systems that mimic a variety of different types of cancer, such as 
breast, lung, liver or bone cancer, with main application in anticancer drug screening and 
fundamental research into cancer metastasis. In neurobiology, most microfluidic devices are based 




microstructures for cell separation, surface micropatterns that guide the adhesion and migration of 
cells and cell manipulators for studies of trauma and regeneration, as well as biosensors for non-
invasive monitoring of cell-to-cell interactions.  
To conclude, microfluidics is a powerful tool and set of techniques for controlling and analysing 

















A permeable on-Chip microvasculature 
for assessing the transport of macromolecules 
and polymeric nanoconstructs 
 
2.1 Introduction 
The human vascular system has a remarkable ability to maintain tissue and cellular homeostasis 
in the body through a complex network of arteries, capillaries, and veins. The smallest vessels – 
the capillaries – are responsible for distributing nutrients and collecting waste from every single 
organ. As such, their walls comprise of only the basal membrane and a monolayer of endothelial 
cells.[67] Transport across capillaries, from the vascular to the extravascular compartment, occurs 
via the paracellular pathway, exploiting openings at the interface among adjacent endothelial cells; 
and the transcellular pathway, using receptors and intracellular vesicles as shuttles to connect the 
two compartments. Depending on the vascular district and the biophysical properties of the agent 
to be transported – small molecules, macromolecules and nanoparticles – the transcellular pathway 
could be more relevant than the paracellular pathway.[45, 68] For instance, very tight intra-
endothelial cell junctions that limits the paracellular pathway in favor of a more selective 
transcellular transport, resulting in an overall modest vascular permeability, characterize the brain 




liver sinusoids – are characterized by a discontinuous or even fenestrated endothelium that 
facilitates the paracellular transport, resulting into a high vascular permeability.[72, 73]  
  
A variety of pathologies, including cancer, atherosclerosis, thrombosis, and more in general, 
inflammatory diseases, are associated with alterations in vascular permeability. [74, 75] For its 
dysregulated and chaotic growth, the cancer neo-vasculature presents a tortuous capillary network 
and large openings – fenestrations – that could range up to several hundreds of nanometers. This 
results in lower perfusion, and blood flow velocities, and higher vascular permeability as compared 
to healthy capillary networks.[76, 77] Similarly, the inflamed vasculature is associated with more 
relaxed endothelial junctions to favor the recruitment of circulating monocytes and other cells of 
the immune system from the vascular network to the diseased tissue.[78] Incidentally, these 
alterations in vascular permeability have been extensively exploited to facilitate the passive 
accumulation of a variety of therapeutic agents at diseased sites. For instance, in cancer therapy, 
the Enhanced Permeability and Retention Effect (EPR) has been invoked over the last 20 years to 
design liposomes, polymeric and metal-based nanoparticles that could accumulate within the 
malignant tissue through the vascular fenestrations and remain in there because of the inefficient 
lymphatic drainage.[77, 79] A similar approach has been also adopted in targeting atherosclerotic 
plaques and the hyper-permeable vascular network in the inflammatory bowel disease.[78, 80]  
 
Traditionally, in vitro models such as the Boyden chamber and in vivo experiments have been used 
to assess the transport properties of macromolecules and nanoconstructs. However, trans-well 




organization and flow conditions.[81] Animal models also present well-known ethical and 
technical limitations.[82] More recently, researchers have been generating functional, endothelial 
networks within microfluidic devices in order to accurately and effectively, study the transport of 
macromolecules and nanoconstructs under different controlled conditions.[83-90] However, most 
vascular systems developed so far comprise of large channels, with a characteristic size much 
larger than 100 m, which are well above that of arterioles and capillaries[84]. Also, 
microchannels formed in tridimensional gels upon the spontaneous organization of endothelial 
cells sufferfrom poor geometrical control and stability over time.[40, 91] Indeed, these systems 
could be thought of as more authentic representations of a microvascular network, but the lack of 
control on geometry, and therefore flow, limits their use in systematic analyses. Furthermore, 
microfluidic systems have been realized with vertically arranged channels replicating a trans-well 
system. However, in general, these systems cannot be efficiently used to quantify vascular 
permeability of molecules and nanoparticles because transport occurs across different optical 
planes. [88, 92-94]  
 
In this work, the vascular permeability of macromolecules and polymeric nanoconstructs, both 
rigid and deformable, was analyzed utilizing a tridimensional model of a human microvessel. This 
was realized in a so-called double-channel microfluidic device where the vascular compartment 
and the extravascular chamber lay on the same geometric plane. Cyclic adenosine monophosphate 
(cAMP), Mannitol and Lexiscan were employed to modulate the vascular permeability from 
physiological to pathological conditions, demonstrating the full potential of the system. After 
assessing the integrity of the vascular endothelial barrier against the FITC-fluorescent Dextran 




adhesion and permeability of 200 nm nanoparticles and 1,000  400 nm discoidal polymeric 
nanoconstructs.  
 
2.2 Materials and Methods 
2.2.1 Chemicals, reagents, and cells 
The following chemicals and reagents were used for the fabrication of the microfluidic chip:  
AZ5214E positive photoresist and the corresponding solvent AZ726MF from Microchem (Italy), 
Chrome etch 18 from OrganoSpezialChemie GmbH (Germany), N-Methyl-2-pyridone from 
Sigma-Aldrich (Italy) as PG Remover and 1H,1H,2H,2H-Perfluoro-octyltrichloro-silane, 97% 
from Alfa Aesar (Germany). For the lithographic process, the following materials were employed: 
a laser-writing machine (DLW6000), an ICP-RIE (Si 500, Sentech Instruments GmbH, Germany) 
for the Bosh process and a Plasma System (Gambetti, Italy) for oxygen plasma treatment. The soft 
lithography process was conducted using polydimethylsiloxane (PDMS) (Sylgard 182) from 
Corning (Italy), glass coversheets No. 1.5H from Deckalaser and biopsy punches with OD = 1 mm 
from Miltex (Italy). As endothelial cell model Human Umbelical Vein Endothelial Cell (HUVEC) 
from PromoCell (USA) were used and cultured in endothelial growth medium according to the 
manufacture’s guideline. [3-4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide] (MTT) 
≥97% from Sigma-Aldrich was used for viability experiment together with a microplate reader 
from Tecan (CH). For integrating the vasculature on the microfluidic chip, the following reagents 
were used: collagen type I solution (≥95%) from bovine skin and Human Fibronectin from Sigma-




performed by using the following reagents and instruments: 250 kDa FITC-Dextran (0.5 µg/mL) 
from Sigma-Aldrich, Fluoresbrite® YO Carboxylate Microspheres 200 nm (2.27 x 109 
particles/mL) from Polysciences (USA), a syringe pump model Harvard Pump 11 Elite from 
Harvard Apparatus (USA), a multirack syringe pump model 230 from Kd Scientific (USA), 
polyethylene tubes (BTPE-50, ID= 0.58 mm, OD=0.97 mm) from Instech Laboratories (Germany) 
and an epi-fluorescent inverted microscope from Leica (Germany) model Leica 6000 (objective 
10x, 0.22 N.A.). For modulating the permeability of the endothelial barrier, the following reagents 
were used: N6,2′-O-Dibutyryladenosine 3′,5′-cyclic monophosphate sodium salt (db-cAMP) 
(≥98.5%), Mannitol (≥98%) and Lexiscan (≥98%) from Sigma-Aldrich. In order to characterize 
the vasculature in the microfluidic device the following instruments were employed: Scanning 
Electron Microscope JSM-6490LV from FEI Company (USA), a Critical Point Drier (CPD) 
K850WM (UK) and a sputter coater model 550 from Emitech (Italy), and an A1-Nikon Confocal 
Microscope from Nikon Corporation (Japan). For immunofluorescence staining protocols, the 
following antibodies and reagents were used: PFA 4% from Santa Cruz Biotechnologies (USA), 
Ms anti-human VE-Cadherin (1:200), AlexaFluor 488 anti-mouse secondary antibody (1:500) 
from Abcam (UK), Hoechst (1 mg/mL) (1:1000) and AlexaFluor 488 Phalloidin from Invitrogen 
(USA). 
 
2.2.2 Microfluidic device fabrication 
Double-channel microfluidic device was fabricated via two lithographic steps, as previously 
reported by the authors with some modifications [95]. Briefly, using a laser-writing machine, a 




membrane were realized. In the first step, the AZ5214E photoresist was used as a positive 
photoresist and spin-coated at 4,000 rpm on a Cr surface. The sample was then baked a 110 °C for 
60 s to clean the resist. The mask including the micropillars was impressed using a mask-aligner 
on the resist at 80 mJ. To develop the resist, the solvent AZ726MF was used. The impressed pattern 
was transferred from the resist to the Cr mask by using a Cr etchant. The residual resist layer was 
then removed from the unexposed surface via PG remover at 80°C for five minutes and a cleaning 
step procedure with ultrapure water. An ICP-RIE Bosh process was performed to dig the 
micropillar membrane over the Si etching down by 5 μm. The obtained Si wafer with the impressed 
micropillar membrane was used in the second step in order to transfer the channels. In this second 
step, the AZ5214E was used as negative photoresist. AZ5214E was spin-coated on the residual Cr 
layer and baked at 110°C for 60 s. Subsequently, the channels mask was aligned on the micropillar 
membrane and then exposed at 95 mJ. Because the resist was used in the reversal mode, the wafer 
required an additional baking phase at 120°C for 120 s and an exposure phase at 300 mJ. The 
development was performed as for the micropillars. A second ICP-RIE Bosh etching was 
performed down to 50 μm, the actual andfinal height of the channels, in order to get both pillars 
and channels on the Si layer. At the end of the lithographic process, the silicon template was 
covered with a layer of silanes by using a desiccator for 1h. The PDMS replica were obtained by 
mixing base and curing agent in a ratio 1:10 (w/w). The PDMS solution was casted on the silicon 
template, degassed until all bubbles were removed and cured at 80°C overnight. The PDMS 
replicas were cleaned with a scotch-tape and inlet and outlet ports were created with a biopsy 
punch. Before bonding the PDMS to a glass coversheet, the PDMS replicas were autoclaved (dry 
autoclave) and dried at 80°C for 4h. In addition, also the glass cover sheets were autoclaved and 




micropillars structure during the bonding step. Oxygen (O2) plasma treatment (pressure = 1.0 
mbar, power = 20 W, time = 20 s) was performed and PDMS replicas were bonded to the glass 
coversheets. The obtained microfluidic chip had a rectangular cross section of 210 μm (width), a 
height of 50 μm and a port-to-port length of 2.7 cm. The micropillar membrane, positioned in the 
middle part of the channels, had a length of 500 μm and a width of 25 μm, with a gap-size between 
pillars of 3 μm. 
 
2.2.3 Extracellular matrix realization 
To mimic the extravascular space, different extracellular matrices (ECM) were realized by mixing 
increasing amount (vol/vol) of Matrigel with a solution of type I collagen. Starting from a stock 
solution of collagen type I (6 mg/mL), a final collagen concentration of 2 mg/mL was obtained by 
using deionized water, 10x EMEM, HEPES buffer 1M and 1M NaOH solution. Seven different 
types of ECM were prepared, starting from 100% of collagen type I and then adding increasing 
volumes of Matrigel© (i.e., 10, 20, 30, 50, 95%) up to 100% of Matrigel©. During the matrix 
manufacturing process, all components were kept at 4˚C to avoid matrix polymerization. In order 
to characterize the ultrastructure, the obtained composite matrices were placed in a petri dish and 
allowed to polymerize in an incubator for at least 30 min (37°C, > 95% humidity).  
 
Extracellular matrix characterization: Scanning Electron Microscopy (SEM). Matrix 
ultrastructure was analyzed using a scanning electron microscope. Samples of the selected matrix 




hours at room temperature, and then post-fixed in 1% OsO4 phosphate buffer for two hours. Then, 
samples were dehydrated through an ascending series of ethanol solutions (30 up to 100%), and 
critical point dried for 1h using CO2. The obtained matrices were sputter-coated with 10 nm of 
gold, and multiple images were acquired with an accelerating voltage of 10 kV and a magnification 
of 5,000. To characterize the structural features of the 3D matrix network, SEM images were 
analyzed using the free software ImageJ. The porosity of the ECM was quantified by using three 
independent images from each sample, binarizing them and calculating the areas of black (pores) 
over the white (fibers) pixels, within the binary images.  
Extracellular matrix characterization: permeability study. Microfluidic devices were autoclaved 
at 120°C for sterilization (wet autoclave) and then dried overnight (>15h) at 80°C. Before 
extracellular matrix filling, microfluidic devices were stored for 1h at 4°C. During the whole 
procedure, matrix solutions were kept on ice. At this point, 10 µL of the selected matrix was 
introduced into the extravascular channel and the loaded devices were transferred at 37°C for 30 
minutes to allow matrix gelation. To characterize the transport of biomolecules within the 
extracellular matrix, 250 kDa FITC-Dextran (0.5 µg/mL) and Fluoresbrite® YO Carboxylate 
Microspheres 200 nm (2.27 x 109 particles/mL) were used. The avascular channel was connected 
to a syringe pump via polyethylene tubing. For all the experiments, the working solutions were 
infused in the avascular channel at a volumetric flow rate of 100 nL/min. Dextran or 200 nm beads 
were infused through the inlet port, allowing to fill completely the avascular channel before 
starting the time-lapse fluorescence acquisition (5s intervals via an epi-fluorescent inverted 
microscope). Time-lapse images were analyzed using ImageJ software, selecting Regions of 
Interest (ROI) in the avascular and extravascular channels. To calculate the permeability 




pressure difference between the channels. Therefore, the permeability coefficient was calcuted 
considering solely diffusion as transport mechanism of solutes across the endothelial monolayer. 
In this experiment, the flux of solute across the monolayer is defined as the rate of exchange of 
dextran molecules or particles within the extravascular region. The concentration is therefore 
directly proportional to the fluorescence intensity. When the avascular channel was fully filled 
with the solution, the permeability coefficient P (µm /s) was calculated as, readapting the equation 






𝑤𝑝𝑖𝑙𝑙𝑎𝑟𝑠 . (𝐼𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 − 𝐼𝑝𝑖𝑙𝑙𝑎𝑟𝑠)𝑡=0
 
 
where AECM  refers to the surface area of the ROI within the extravascular space reported in µm2; 
If  is the total fluorescence intensity of the extravascular region at the final time and Ii at t=0; wpillars  
is the width of the pillars across which diffusion occurs, expressed in µm; Ivascular is the total 
fluorescence intensity of the vascular channel once completely filled and Ipillars is the total 
fluorescence intensity of the interface between the vascular region and the ECM region, both at t 
= 0. Δt is the time interval between t = 0 and the final time of the experiment, expressed in s.  
 
2.2.4 Vascular endothelium in the microfluidic device 
To mimic the extravascular compartment, a 80% collagen type I - 20% Matrigel© matrix was 




incubated for 2h at 37°C. HUVEC were cultured till confluence (~80%) and then trypsinized, 
counted and concentrated to 5106 cells/mL. Cells were used until passage 6 (P6). For complete 
coverage of the PDMS walls, a double seeding procedure was used. In the first step, 10 µL of cell 
suspension was added through the inlet port of the vascular channel and immediately the 
microfluidic chip was flipped facing upside-down to promote endothelial cells adhesion to the top 
of the channel. In this configuration, microfluidic chips were incubated at 37°C, 5% CO2 for 1h. 
A second cell-seeding step was performed, without flipping the microfluidic chip, allowing the 
adhesion of the endothelial cells to the bottom of the channel. Devices were incubated at 37°C for 
2h.  Micropipette tips, filled with 200 µL of culture media, were connected to inlet ports of the 
vascular channel, while empty tips were placed in the corresponding outlets. The inlet and outlet 
ports of the extravascular channel were connected with tips filled with 50 µL of culture media. 
Cell culture medium was changed every 12h. HUVEC were cultured to reach confluence 
(approximately 2 days) in order to form a continuous monolayer before conducting permeability 
experiments.  
db-cAMP treatment to tune the vascular permeability. In order to strengthen, the endothelial 
barrier, HUVEC were treated with increasing concentrations of N6,2′-O-Dibutyryladenosine 3′,5′-
cyclic monophosphate sodium salt (db-cAMP). After 2h from the cell seeding, endothelial cells 
were treated until confluence with 25, 50, 100 or 200 µg/mL of db-cAMP, respectively. Due to the 
reduced paracellular permeability observed, in the following experiments HUVEC were cultured 
with 25 µg/mL of db-cAMP.  
Endothelial cells viability. To assess the effect of db-cAMP on HUVEC viability and proliferation, 




dehydrogenase to blue formazan product. Briefly, 105 cells/well were seeded in 96-well plates and 
incubated at 37◦C, 5% CO2, for 24 h. Next, the medium was replaced with Endothelial Cell Growth 
Medium containing the corresponding concentrations of db-cAMP (25, 50, 100 and 200 µg/mL). 
After 24, 48 and 72 h of incubation, the MTT solution (5.0 mg/mL PBS) was diluted in Endothelial 
Cell Growth Medium (0.25 µg/mL), added to each well and incubated at 37◦C for 4 h. The resulting 
formazan crystals were dissolved by adding ethanol (200 µL/well), and the absorbance was read 
at 570 nm using a microplate reader. Controls (i.e., cells that had received no treatment) were 
normalized to 100% and readings from treated cells were expressed as the percentage of viability 
inhibition. Five replicates were considered for each data point. 
Mannitol and Lexiscan treatment to tune the vascular permeability. For modeling the opening of 
the vascular endothelium, Mannitol 1M was infused in the vascular channel for 5, 15 and 30 
minutes after achieving cell confluence.  1µM of Lexiscan was infused into the vascular channel 
and permeability calculated after 5, 15, and 30 minutes of treatment. Permeability analyses were 
conducted as previously reported. 
 
2.2.5 Discoidal polymeric nanoconstructs (DPN) permeability and 
adhesion study 
Discoidal polymeric nanoconstructs (DPN) were synthesized by employing a top-down fabrication 
process, as already reported by the authors [96-99]. For the experiments, two types of DPN were 
fabricated, soft, deformable DPN (sDPN) and rigid DPN (rDPN). Briefly, a polymeric mixture 




the wells of the sacrificial PVA template and exposed to UV-light for polymerization. PVA 
templates were dissolved in water and particles collected through centrifugation. Lipid Rhodamine 
B (Avanti Polar Lipids, USA) was added to the polymeric paste composing the DPN for 
permeability experiments, while Lipid-Cy5 synthetized by the authors was used for adhesion 
experiments [100]. On day two post seeding, the permeability of HUVEC monolayers to both DPN 
configurations (500106 particles/mL) was tested as reported previously. For the adhesion study, 
a multi-rack syringe pump was placed inside a cell incubator and loaded with 1 mL syringes. The 
vascular channel was perfused with sDPN and rDPN (50106 particles/mL) with and without 
endothelial cells at 0.1 µL/min (0.2 dyne/cm2) , 0.25 µL/min (0.7 dyne/cm2 )  and 0.5 µL/min (1 
dyne/cm2), corresponding to the tumor flow rate, an intermediate flow rate and physiological flow 
rate, respectively.[101] Channels were then flushed with culture medium to remove non-adhering 
particles and fixed with 4% PFA for 15 min. Nanoconstruct adhesion was immediately 
investigated using an A1-Nikon confocal microscope.  
 
2.2.6 Electron Microscopy Imaging 
Vascularized microfluidic chips were imaged via scanning electron microscopy. Cells in the 
vascular channels were fixed in 2% glutaraldehyde in 0.1M sodium cacodylate buffer, pH 7.3 for 
1h at room temperature. Subsequently, the PDMS chips, with endothelial cells adhered to the 
channel walls, were detached from the glass coversheets and post-fixed in 1% OsO4 phosphate 
buffer for two hours. The samples were then dehydrated through ascending series of ethanol 
solutions (30% up to 100%), followed by a solution of 1:1 ethanol:hexamethyldisilazane (HMDS, 




microfluidic chips were sputter-coated with 10 nm of gold and images acquired with accelerating 
voltage of 10 kV. 
 
2.2.7 Cells immunofluorescence staining 
Endothelialized vascular channels were fixed with 4% of PFA for 20 min at room temperature. 
Following fixation, channels were washed three times with cold PBS, permeabilized with a 
solution of Triton X 0.3% in PBS for 15 min and incubated with 20% of goat serum solution 
diluted in PBS for 1h at 4 °C. Endothelial Cadherins were targeted with antihuman VE-cadherin 
antibody overnight at 4°C with 10% of goat serum. The unbound antibody was removed with three 
washes of cold PBS. After that, microfluidic chips were incubated with a solution of Alexa Fluor 
488 anti-mouse secondary antibody (1:500) with 10% of goat serum for 2h at 4°C. Cells were 
washed again three times with cold PBS and incubated with a solution of PBS and 1:1000 Hoechst 
for 30 min at room temperature. F-actin cytoskeleton was stained in green using Alexa Fluor™ 
488 Phalloidin according to the supplier instructions. Images were acquired using an A1-Nikon 
confocal microscope. 
 
2.2.8 Statistical analysis 
All data are presented as the mean ± SD using GraphPad Prism5 software. Calculation of porosity 
was analyzed via 1-way ANOVA. p – values < 0.05 were denoted with * ,p – value < 0.01 with 
**. Permeability studies and DPN adhesion studies were evaluated via 2-way ANOVA analysis of 




< 0.01 with **, and p – values < 0.001 with ***. For all experiments, at least 5 independent 
repetitions were conducted. 
 
2.3 Results 
2.3.1 Architecture of the double-channel microfluidic device: the 
vascular compartment 
A soft-lithographic approach was employed to create an optically-clear poly(dimethyl siloxane) 
(PDMS) double-channel microfluidic device (Figure 2.1A), following previous works by the 
authors. [87, 95] The microfluidic device is composed of two parallel channels interconnected in 
the central section via an array of micropillars, realizing a permeable membrane (Figure 2.1B). 
Specifically, this central permeable section has a characteristic length of 500 µm and an inter-pillar 
gap size of  3 µm, as detailed by the scanning electron micrograph shown in the right inset of 
Figure 2.1B. As previously reported [87], curved pillars provide higher bending stiffness, lower 
adhesive interactions and smaller inter-channel separation distance. Specifically, the 10- µm  wide 
curved pillars, laying parallel to the flow, offer higher mechanical stability. Such a configuration 
realizes a physical separation between the two channels supporting the identification of the two 
different biological compartments – the vascular and the extravascular space – without hampering 








Figure 2.1. Recapitulating human vasculature in the double channel microfluidic device. A) Photograph (left) 
and schematic illustration of a double-channel microfluidic device with HUVEC cultured on all surfaces of the 
vascular channel. B) SEM images showing the double-channel microfluidic structure and the micropillars geometry 
(Scale bar 100 µm and 5 µm for inset on the right ) . C) SEM micrographs of endothelial cells adhering to the PDMS 
walls (Scale bar 100 µm left image, 20 µm right image ) . D) Immunofluorescence images of HUVEC barrier. In the 
microfluidic device nuclei (blue) and VE-cadherin (green) were stained. Cross sectional view (left) of the endothelial 




To build a physiologically relevant and vascularized organ-on-chip, the upper channel was 
designed to accommodate endothelial cells (the vascular compartment) while the bottom channel 
was filled with extravascular matrix components (the extravascular compartment).  
Human umbilical vein cells (HUVEC) were cultured in the vascular compartment over a 
fibronectin-coated PDMS surface and let to spread, grow and stably adhere, as documented in 
Figure 2.1C. Specifically, HUVEC were seeded in the upper channel after treating the PDMS 
surface with 50 µg/mL of human fibronectin for 2 hours.  
 A double-step cell seeding procedure was employed to entirely cover the walls of PDMS channel. 
After fibronectin coating, HUVEC were gently pipetted into the vascular channel, and the 
microfluidic chip was immediately flipped. In this configuration, HUVEC were left to adhere to 
the top surface of the channel for 1h, at 37°C. Then, the microfluidic chip was flipped again, 
HUVEC were pipetted into the vascular channel in order, this time, to cover the bottom surface. 
A detailed analysis with confocal fluorescence microscopy revealed the formation of a continuous 
endothelial monolayer covering the bottom, top and later walls of the vascular compartment even 
next to the pillar membrane (Figure 2.1D). The right inset of Figure 2.1D also shows a lateral 
projection of the confocal microscopy images demonstrating that the endothelial cells uniformly 
coat the vascular compartment’s surface along its entire rectangular cross section. Moreover, the 
staining of the VE-Cadherin proteins (green) demonstrates the formation of inter-endothelial cell 





2.3.2 Architecture of the double-channel microfluidic device: the 
extravascular compartment 
On the other side of the micropillar membrane, the extravascular compartment was filled with 
components of the extracellular matrix (ECM), including Matrigel© and Collagen type I. To finely 
modulate the ECM permeability, the relative ratio between the two components was varied from 
100% Matrigel© (8.6 mg/mL) to 100% Collagen (2 mg/ml) realizing seven different matrix 
configurations (see Table 1).  
 
Representing scanning electron microscopy images of four matrix configurations are shown in 
Figure 2.2A, specifically for the case of 100% Collagen (left); 80% Collagen and 20% Matrigel©; 
50% Collagen and 50% Matrigel©; 100% Matrigel© (right). This series of images qualitatively 
Table 1.  Extracellular Matrix Characterization. Table recapitulating collagen type I and 




shows that the progressive increase in Matrigel© content is associated with a decrease in matrix 
permeability.  
The first image on the left, which is associated with a Collagen only matrix, shows fibrils arranged 
to form pores over multiple scales and certainly comparable in size to that of a cell. As the 
Matrigel© content increases, the Collagen fibers appear to entangle more forming denser 
structures. At 20% (v/v) Matrigel©, the gel is composed of thicker fibers still preserving the 
original porosity of the network. At 50% (v/v) Matrigel©, the collagen fibers are packed into a 
dense matrix with a drastically reduced network porosity as compared to the previous 
configurations. Finally, the  image on the right, which is associated with a Matrigel© only matrix, 
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Figure 2.2. Extracellular matrix characterization. A) SEM micrographs of the extracellular matrix showing the 
increasing Matrigel© content and the relative porosity (Scale bar 5 µm). C) Porosity percentage was calculated via 





shows a continuous network in which individual pores and fibers cannot be distinguished anymore 
at the considered magnification.  
The electron microscopy images were further analyzed using ImageJ to extract quantitative 
information on the matrix porosity (Inset Figure 2.2A). Figure 2.2B shows the porosity variation 
as the Matrigel© content in the extracellular matrix increases. As expected, the porosity of the 
hydrogel reduces from 51 ± 4.6% for a Collagen only matrix to 2 ± 1.04 % for a Matrigel© only 
matrix. Here it is important to highlight that SEM images, and the corresponding porosity analyses, 
were obtained on dehydrated matrices, as required by the imaging technique.  
 
To investigate further the gel porosity in an actual functional assay, permeability studies were 
conducted on the seven matrix configurations using two different fluorescent tracers, namely the 
250 kDa FITC-Dextran (green) and 200 nm polystyrene beads (red). These tracers were infused 
from the vascular compartment and observed as they slowly permeated the extravascular space. 
Dynamic Light Scattering (DLS) analyses of the two tracers returned a hydrodynamic diameter of 
12.86 ± 3.74 nm for the Dextran molecules and 181 ± 31 nm for the beads (Table 2). The estimated 
permeability values are given in Figure 2.2C and confirm that, for both tracers, the gel 




with the larger 200 nm polystyrene beads is overall smaller than that registered for the  10 nm 
Dextran molecules. A rapid decrease in permeability was observed between 20 and 30% of 
Matrigel© content. For higher Matrigel© contents, the permeability of the 200 nm polystyrene 
beads went to zero whereas it plateaued around  0.2 m/s for the Dextran molecules. Based on 
these observations and data from the current literature [90, 102], an extracellular matrix with a 
20% Matrigel© content was selected for the extravascular compartment of the microfluidic chip 
to recapitulate the ECM composition through fibrillar collagen type I and proteins associated with 
Matrigel©. This matrix configuration offered a proper balance between molecule and particle 
permeability, while ensuring that the extravascular compartment was enriched with unique growth 
factors for cell culture.  
 
2.3.3 Reducing the vascular permeability to circulating agents 
The integrity of the endothelial barrier across the micropillar membrane was tested using the same 
two fluorescent tracers adopted for the ECM characterization. The tracers were slowly infused 
through the vascular compartment and their permeation into the extravascular space was assessed 
via fluorescent microscopy in the absence ( HUVEC) and presence (+ HUVEC) of endothelial 
cells. From the post-processing of the fluorescent microscopy acquisitions, it resulted that the 250 
kDa FITC-Dextran molecules would readily flow across the micropillar membrane returning a 
permeability of 1.35 ± 0.3 µm/s. The formation of a continuous monolayer of endothelial cells (+ 
HUVEC) significantly reduced this permeability value to 0.93 ± 0.30 µm/s, thus confirming the 
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Figure 2.3. Strengthening of endothelial barrier. A) Permeability coefficients calculated for 250kDa-FITC Dextran 
and Microspheres 0.2 µm on microfluidic chip without HUVEC (-HUVEC), on endothelialized microfluidic chip (+ 
HUVEC) and on endothelialized chip treated with 25 µg/mL of db-cAMP (+db-cAMP) (n≥5). B) Representative 
fluorescence images of Dextran (left) and  Spherical beads (right) diffusion at 0.1 µL/min without endothelial cells (-
HUVEC), with untreated endothelium (+ HUVEC) and with db-cAMP at a concentration of 25 µg/mL (Scale bar 250 
µm) . C) Immunofluorescence images of human umbilical vein endothelial cells (HUVEC) with and without db-cAMP 




For the 200 nm beads, the permeability value in the absence of HUVEC was 0.88 ± 0.18 µm/s and 
reduced dramatically to 0.04 ± 0.005 µm/s in the presence of HUVEC (Figure 2.3A). Importantly, 
in the absence of HUVEC, the permeability of the Dextran molecules and 200 nm beads into the 
extravascular space werecomparable. However, the addition of HUVEC induced a much larger 
decrease in permeability for the 200 nm beads as opposed to the 10 nm macromolecules, resulting 
in a 30% vs 95% reduction, respectively. This demonstrated the size-dependent selectivity of the 
micropillar membrane. 
To further modulate the permeability of the endothelial layer, cells were treated with Dibutyryl-
cAMP (db-cAMP). This is an activator of cAMP-dependent protein kinases that is known to reduce 
vascular permeability by inducing changes in the endothelial cell-cell junctional proteins, like VE-
cadherin [103]. Endothelial cells were treated with db-cAMP, ranging from 25 to 200 µg/mL, and 
tested for the permeability to 250 kDa FITC-Dextran molecules.  
A 3-fold decrease in permeability was observed already at 25 µg/mL db-cAMP, from 0.93 ± 0.30 
to 0.27 ± 0.24 µm/s (Figure 2.4A). Similar permeability values were reported at higher db-cAMP 
concentrations (Figure 2.4A). Moreover, cell viability studies showed that treating endothelial 
cells with 25 µg/mL db-cAMP did not induce any significant toxicity up to 72h. On the other hand, 
some moderate toxicity returning a cell viability of  70% was documented at the higher db-cAMP 
concentrations and longer incubation times Figure 2.4B). For this reason, all the experiments were 
conducted by culturing endothelial cells with 25 µg/mL db-cAMP. Note also that, not surprisingly, 
the reduction in permeability observed for the  10 nm FITC-Dextran molecules was not 
recapitulated for the larger 200 nm polystyrene beads. For these larger agents, a dramatic reduction 




treatment with 25 µg/mL db-cAMP returned a permeability of 0.05 ± 0.04 µm/s, which was 
statistically similar to the untreated case (0.04 ± 0.005 µm/sec – p = 0.6890).  
Confocal images of endothelial cells treated with 25 µg/mL of db-cAMP documented a higher 
density of VE-cadherin proteins (green) as compared to the untreated case (Figure 2.3C), further 
confirming the generation of tighter inter-endothelial bonds. 
 















































Figure 2.4. db-cAMP treatment on endothelial cells. A) Permeability coefficient 
for 250kDa-FITC Dextran after treatment of endothelial monolayer with different 
concentration of db-cAMP. (n≥5). B) Cell viability of HUVEC over 72h with 




2.3.4 Increasing the vascular permeability to circulating agents 
In drug delivery and biomedical imaging, the transient and reversible opening of the blood vessel 
walls is key to support the accumulation of molecules and nanocarriers in the diseased tissue. 
Therefore, to further characterize the functionality of the vascular endothelium in the microfluidic 
chip, two different permeation enhancers were considered, namely Mannitol and Lexiscan.  
The first agent, Mannitol, is clinically used to reduce excessive intra-tissue pressure, especially in 
the brain as its application causes an osmotic shrinkage of the endothelial cells and enhances the 
BBB permeability.[104] In accordance with other studies, a 1M Mannitol solution was infused 
into the vascular compartment under physiological conditions (37°C, 5% CO2, > 95% of humidity) 
for 5, 15 and 30 minutes. Then, the permeability of the endothelial layer was assessed, following 
the same protocol described above, by infusing 250 kDa FITC-Dextran molecules and 200 nm 
polystyrene beads at 0.1 µL/min (Figure 2.5A).  
The osmotic opening of the endothelial layer resulted in an increased, time-dependent 
extravascular accumulation for both 250 kDa FITC-Dextran molecules and 200 nm beads. For the 
Dextran molecules, the permeability values (+ HUVEC and +db-cAMP) increased from 0.27 ± 
0.24 to 0.56 ± 0.10 µm/s, to 0.78 ± 0.09 µm/s and 0.99 ± 0.06 µm/s after 5, 15 and 30 minutes of 
continuous infusion of mannitol, respectively (Figure 2.5A). A 30-minutes treatment with 
Mannitol  increased the permeability by over 3 times. Notice that in the absence of HUVEC, the 
permeability of Dextran was equal to 1.37 ± 0.2 µm/s indicating that the Mannitol treatment was 
almost equivalent to transiently removing the endothelial layer. For the 200 nm beads, the 
permeability values (+ HUVEC and +db-cAMP) increased from 0.029 ± 0.01 to 0.06 ± 0.02 


























































































Figure 2.5. Modulation of Vascular Permeability. Endothelial barrier integrity under hyperosmotic conditions 
(A) and under Lexiscan treatment (B) monitored by measuring permeability coefficient via fluorescence 
microscopy (n≥5). Representative fluorescence images of Dextran (left) and 200nm Polystyrene Beads (right) 
diffusion at 0.1 µL/min with untreated HUVEC, after 30 minutes treatment of Mannitol and after 15 minutes 




respectively (Figure 2.5A). This resulted in a 10-fold increase in the accumulation of 200 nm 
beads into the extravascular compartment (Figure 2.5C).  
Despite multiple successes with mannitol, the non-uniform effect among different brain regions 
and negative side effects (e.g., epileptic seizure) has limited the clinical application of this 
procedure. [105] A more recent approach is based on the manipulation of the Adenosine Receptors 
(AR) using the FDA-approved A2A AR agonist (Lexiscan®). As with Mannitol, Lexiscan  
modulates cytoskeletal organization reflecting a down-regulation of both adherent and tight 
junctions. [106, 107]  
In the proposed microfluidic device, a Lexiscan treatment (1 µM) was conducted as per the 
Mannitol. For 250 kDa FITC-Dextran, a plateau in permeability was reached already at 15 min of 
treatment returning a value of 0.64 ± 0.09 µm/s. At 30 minute of treatment, the permeability 
slightly but not significantly decreased down to 0.54 ± 0.23 µm/s (p = 0.5124) (Figure 2.5B). 
Thus, for dextran macromolecules, the infusion of Lexiscan induced an overall 2-fold increase in 
vascular permeability. A similar trend was also observed for the 200 nm beads for which a plateau 
was reached after 15 minutes of treatment with a permeability value of 0.24 ± 0.01 µm/s (Figure 
2.5B). No change in permeability was documented at the longer treatment time of 30 minutes. 
However, differently from the 250 kDa FITC-Dextran, this was still sufficient to realize a 10-fold 
increase in vascular permeability. Indeed, no significant statistical difference was observed in 
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Figure 2.6. Remodeling of AJs. Immunofluorescence images of endothelial adherent junctions remodeling 
after treatment with A) 1M Mannitol and B) 1µM Lexiscan overtime. VE-cadherin  are stained in green. Scale 
bar 50 µm.  C) Cross sectional view of endothelial vascular channel and remodeling after vascular opening. 





The effect of the two vascular permeabilizers on the expression of VE-Cadherins and the 
organization of the actin cytoskeleton was then analyzed. The exposure of endothelial cells to 
hyperosmotic agents – Mannitol – resulted in the detachment of adjacent cells as documented by 
the drop in VE-cadherin expression  after just 5 minutes of treatment (Figure 2.6A).  
A similar behavior was also documented with Lexiscan (Figure 2.6B). However, in the case of 
Lexiscan, the opening of endothelial barrier was reversible and at 30 minutes of treatment, VE-
Cadherin proteins started to appear again on the cell membrane and reassemble to form new 
intracellular bonds (Figure 2.6B). These results confirmed the enhanced paracellular permeability 






2.3.5 Assessing the vascular dynamics of circulating polymeric 
nanoconstructs 
The proposed microfluidic device was used to study the transport of blood-borne nano- and micro-
particles from the vascular to the extravascular compartments. In this context, three different types 
of particles were tested and compared: 200 nm polystyrene beads (PB), soft discoidal polymeric 
nanoconstructs (sDPN), and rigid discoidal polymeric nanoconstructs (rDPN). DPN are disc 
shaped nanoconstructs, with a 1,000 nm diameter and 400 nm height, and were fabricated 
following a soft lithography templating technique (Figure 2.7A-B).[96-99] 
 These particles resulted from mixing together the biocompatible and biodegradable polymers, 
poly (lactic-co-glycoli acid) (PLGA) and polyethyleneglycol diacrylate (PEG-DA). Previous 
studies have shown that the mechanical stiffness of these particles could be modulated by tailoring 
the content of PEG-DA in the formulation. [97] 
First, vascular permeability experiments were carried out with soft and rigid DPN under low flow 
conditions. Both sDPN and rDPN were not able to cross the endothelial layer, even following 







Figure 2.7. Polymeric Nanoconstructs. A) Schematic illustration of sDPN (blue) and rDPN (orange). (B) Confocal 




Specifically, in the absence of HUVEC, the permeability values were equal to 0.019 ± 0.002 
µm/sec and 0.014 ± 0.001 µm/sec (p = 0.595) for the sDPN and rDPN, respectively. After the 
inclusion of endothelial cells, the vascular permeability reduced further falling in the range of 
0.007 ± 0.001 µm/sec, with no significant difference between the two nanoconstructs. Treatments 
with Mannitol and Lexiscan did not enhance the permeation of DPN. In addition, the 200 nm PB 
beads generally returned a vascular permeability about two orders of magnitude higher than that 
observed for DPN under all the tested conditions. Representative images for the different tested 
conditions are provided in Figure 2.8B-D. Indeed, the permeability values documented in Figure 
2.8A were expected given the size of the discoidal nanoconstructs, which have been designed to 
target the malignant vasculature rather than extravasating at sites of vascular hyperpermeability. 
[96, 99]  
Then, vascular adhesion experiments were performed under three different conditions: a low 
capillary flow condition (low flow), which is characterized by a flow rate of 0.1 µL/min (wall 
shear stress  0.03 Pa; average velocity  0.2 mm/s) as opposed to a physiological capillary flow 
condition (physiological flow), which is characterized by a flow rate of 0.5 µL/min (wall shear 
stress  0.15 Pa; average velocity of   1 mm/s); and an intermediate flow condition characterized 
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Figure 2.8. Permeability of Polymeric Nanoconstructs. A) Permeability coefficient and endothelial modulation for 
200nm Polystyrene Beads, sDPN and rDPN (n ≥ 5). p<0.001 denoted with ***. B) Representative fluorescence images 
of 200nm Polystyrene Beads diffusion at 0.1 µL/min with untreated HUVEC, after 30 minutes treatment of Mannitol 
and after 15 minutes treatment of Lexiscan (Scale bar 250 µm). C) Representative fluorescence images of sDPN (left) 
and  D) rDPN (right) diffusion at 0.1 µL/min with untreated HUVEC, after 30 minutes treatment of Mannitol and after 




Interestingly in the absence of HUVEC, DPN appeared to be attracted and entrapped at the micro-
pillar membrane rather than adhering on the fibronectin-coated PDMS of the main channel (Figure 
2.9A sDPN – top row; rDPN – bottom row).  
Note that the matrix filling the extravascular compartment would favor the formation of 
‘openings’, similar to fenestrations in a malignant vasculature, at the micro-pillar interface where 
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Figure 2.9. Adhesion of DPN. A) Representative confocal fluorescence images of sDPN, rDPN labeled with Cy5 
adhering to the PDMS walls without HUVEC under tumor flow condition, intermediate and physiological flow 
condition(Scale bar 100 µm). B) Adhesion of sDPN and rDPN within the channel under different flow conditions in 
the absence of the endothelial layer (n ≥ 3). C) Adhesion of sDPN and rDPN at the micropillar mebrane under different 




soft and rigid configurations. However, the soft DPN showed a stronger tendency than the rigid 
DPN to be entrapped at the micro-pillar interface forming almost a continuous layer of particles at 
the highest flow rates (Figure 2.9A). The bars in the chart of Figure 2.9B-C return the amounts 
of adherent DPN, expressed in terms of fluorescent intensity, within the channel and at the micro-
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Figure 2.10. Adhesion of DPN to the endothelium. A) Representative confocal images of sDPN and rDPN labeled 
with Cy5 adhering to the endothelial layer under tumor, intermediate and physiological flow conditions. B) Adhesion 
of sDPN and rDPN to the endothelial layer under different flow conditions (n ≥ 6).  p< 0.05 denoted with *, p< 0.01 





In the presence of endothelial cells, a different behavior was observed. Under this condition, the 
micro-pillar membrane was no more an attractor for DPN as the vascular cells would prevent the 
formation of openings. Adhesion within the channel on the HUVEC was instead preferred by DPN 
(Figure 2.10A, sDPN – top row; rDPN – bottom row).  
Interestingly, the soft DPN were observed to adhere at low flow rates more than rigid DPN. The 
opposite trend was instead observed at the higher flow rates. This is summarized in the bar chart 
of Figure 2.10B. Under low flow conditions, a fluorescence intensity value equal to 43 ± 9.35 AU 
was measured for sDPN as opposed to 23 ± 5.77 AU for rDPN (p = 0.0006). Under physiological 
flow conditions, adhering rDPN were associated to a fluorescence intensity of 44 ± 2.8 AU while 
for the sDPN the value was almost two times lower 26 ± 6.0 AU (p = 0.004) (Figure 2.10B). 
Under intermediate flow conditions, sDPNand rDPN displayed no difference in vascular adhesion 
documenting a smooth transition from low to high flow rate conditions.  
 
2.4 Discussion 
In drug delivery and biomedical imaging, systemically administered molecules and nanomedicines 
must either escape the vascular compartment and distribute within the diseased tissue (tissue 
targeting) or firmly adhere to the diseased vasculature (vascular targeting) in order to properly 
exert their curative and diagnostic functions. This process is strictly regulated by several factors 
including the local hydrodynamic conditions and vascular permeability. As such, assessing the 
efficacy of drug delivery systems in vitro requires the design and realization of microfluidic 




modulated reproducing physiological and pathological conditions. This need has inspired the 
engineering of a double-channel microfluidic device (Figure 2.1) that integrated a vascular 
compartment and an extravascular chamber. The vascular compartment, with a width of 200 µm 
and a height of 50 µm, matched the characteristic dimensions of arterioles and large capillaries 
and was coated by endothelial cells [108, 109]. The extracellular matrix underlying the vascular 
endothelium provides simultaneously a mechanical function, supporting the blood vessel walls, 
and a biological function, mediating signals involved in endothelial cell proliferation, migration, 
morphogenesis, survival, and angiogenesis. This is achieved by multiple properly mixed 
components, including collagen I, III and IV, different laminin types, perlecan and other less 
abundant proteins and fibers. Matrigel© is rich in laminin, collagen type IV, and perlecan, thus 
approximating the composition of the vascular basement membrane. This observation triggered 
the realization of a biologically inspired ECM composed of collegen type I and Matrigel© (Figure 
2.2) [110, 111]. Seven different collagen/Matrigel© combinations were considered and 
characterized for their permeability, as documented in Figure 2. The combination 80% of collagen 
and 20% of Matrigel© returned physiologically relevant permeabilities to 250 kDa FITC-Dextran 
molecules. Higher Matrigel© concentrations were excessively impermeable to molecules and 
cells, whereas a 100% collagen type I matrix would have lacked collagen type IV, laminin and 
other fiber and proteins that are contained in Matrigel© as well as in the vascular basement 
membrane. 
 
With such a system, first, the formation of a continuous endothelial barrier in the vascular 




endothelial barrier (Figure 2.1C); confocal fluorescent microscopy, to document the expression 
of VE-cadherin molecules (Figure 2.1D and Figure 2.6); and dynamic assays to quantify the 
vascular permeability of 250 kDa Dextran molecules and 200 nm polystyrene beads (Figure 2.2C). 
The proper deposition and culturing of HUVEC within the microfluidic device prompted the 
formation of a continuous endothelial layer on the micro-pillar membrane leading to permeability 
values as low as 0.93 ± 0.30 µm/s for the 250 kDa Dextran molecules and 0.04 ± 0.005 µm/s for 
the larger 200 nm polystyrene beads. The vascular permeability for the macromolecules (250 kDa 
Dextran molecules  10 nm particles) was further reduced to 0.27 ± 0.24 µm/s upon exposing the 
endothelial cells to db-cAMP (Figure 2.3,2.4). These permeability values were in line with those 
documented for other vascular microfluidic platforms [39, 112-114] and only slightly higher than 
those measured in vivo in the case of macromolecules [115]. Indeed, the current microfluidic 
device configuration includes only a layer of endothelial cells without perivascular supportive 
cells, such as pericytes, smooth muscle cells and fibroblasts that would reduce further the vascular 
permeability. [116, 117] Despite this, it should be highlighted that the treatment with db-cAMP 
did not affect the permeability for the 200 nm particles, suggesting that the proposed endothelial 
barrier could be accurately and efficiently employed to study the vascular transport of 
nanoparticles. The ability to modulate the vascular permeability was demonstrated further by 
infusing directly into the microfluidic devices Mannitol and Lexiscan. The exposure of the 
otherwise continuous endothelial layer to these permeabilizing agents resulted in an increase in 






After demonstrating the ability to precisely tune the vascular permeability from physiological to 
pathological values, the microfluidic device was used to study the dynamics of blood borne 
polymeric nanoconstructs. Specifically, in addition to the commercially available 200 nm 
polystyrene beads (PB), soft and rigid 1,000  400 nm discoidal polymeric particles (DPN) were 
considered. Here it is important to recall that while conventional nanoparticles, with a 
characteristic size of 100 – 200 nm, are expected to cross the hyperpermeable endothelial layer, 
DPN were  designed to drift across the streamlines, in a process known as margination; firmly 
stick to the diseased vasculature; and release thereof their therapeutic cargo and imaging 
molecules.[99] In this context, the microfluidic device was used to evaluate the ability of soft and 
rigid DPN to marginate and adhere to the endothelial barrier under different flow and permeability 
conditions. In particular, the DPN behavior was tested at flow rates ranging from 0.1 µL/min (100 
µm/s), mimicking sub-physiological, quasi-tumoral flow conditions, to 0.5 µL/min ( 1 mm/s), 
reproducing more physiologically relevant flow conditions.[101] As expected, neither the sDPN 
nor the rDPN were able to cross the micropillar membrane and diffuse deep into the extravascular 
compartment.  
In the absence of endothelial cells, all the walls of the microfluidic device were solely coated by a 
layer of fibronectin and appeared as relatively flat interfaces. Differently, however, the micro-
pillar membrane zone appeared as a wavy interface with repetitive valleys and crests, still coated 
by the fibronectin layer. In this configuration, both rDPN and sDPN were observed to 
preferentially accumulate at the micro-pillar membrane as opposed to the top, bottom, and lateral 
walls of the device (Figure 2.9A-C). The number of entrapped rDPN was almost constant over a 
wide range of flow rates. Although, at higher flow rates, rDPN were also observed to adhere at the 




higher extent than rDPN, in a shear flow dependent manner (Figure 2.9C). Also, differently from 
rDPN, no significant accumulation of sDPN was observed on the bottom of the device, even at 
higher flow rates (Figure 2.9B). This preferential accumulation of DPN at the micro-pillar 
membrane, in the absence of endothelium, should be associated to the direct geometrical 
entrapment of those nanoconstructs moving in proximity of the irregular, wavy interface. Also, the 
deformable sDPN could be more easily entrapped, as opposed to their rigid counterpart, as the 
local shear rate increased. However, this could only partially explain the dramatic difference 
observed when comparing soft versus rigid DPN (Figure 2.9C). Possibly, an additional 
contribution to sDPN accumulation could be derived by a direct, hydrodynamic-based attraction 
of these nanoconstructs to the micro-pillar membrane. While it is well known that deformable 
particles moving in proximity of a flat wall would tend to be pushed towards the center of the 
channel by dominating lift forces [118], only recently computational analyses have demonstrated 
that deformable particles moving in proximity of a wavy interface could migrate away from the 
center toward the wall. [119] This hydrodynamic-based attraction would depend on the amplitude 
 of the wall waviness, the ratio between the wavelength  and the characteristic size R of the 
particle, and the local flow conditions. Importantly, this hydrodynamic-based attraction would 
only apply to deformable particles. Indeed, only an ad hoc computational analysis accounting for 
the specific micro-pillar membrane geometry, flow conditions and particle properties could help 
evaluate the relative importance of hydrodynamic-based attraction over geometrical entrapment.  
For an endothelialized vascular compartment, the waviness of the micro-pillar membrane is 
massively reduced and DPN geometrical entrapment cannot occur anymore (Figure 2.10A). 
Notice, incidentally, that this was an additional demonstration of the proper endothelial coating of 




formed a continuous monolayer with a moderate waviness whose amplitude is now related to the 
cell nuclei. For the soft DPN, hydrodynamic-based attraction would be minimal and could 
outperform lift forces at the wall only at low flow velocities. This could explain the higher 
deposition observed for the sDPN at low flow rates (Figure 2.10B). For the rigid DPN, the 
margination velocity would tend to grow with the flow rates thus explaining the larger particle 
deposition at higher flow velocities.[120] Even in this case, only an ad hoc computational analysis 
could help to univocally identify the governing mechanisms regulating the behavior of different 
DPN. However, this is beyond the scope of the current work and certainly constitutes the starting 
point for future studies on vascular dynamics of soft versus rigid, non-spherical particles. 
 
2.5 Conclusions 
A double-channel microfluidic device was demonstrated to study the transport of macromolecules 
and nanoconstructs under different vascular conditions. A vascular compartment was covered by 
a continuous layer of endothelial cells, whereas an extravascular chamber was filled with a mixed 
collagen-Matrigel© matrix. After demonstrating the integrity of the endothelial barrier using 
different complementary techniques, the vascular permeability of macromolecules (250 kDa 
FITC-Dextran), nanoparticles (200 nm polystyrene beads), and polymeric nanoconstructs (1,000 
 400 nm discs) was characterized under physiological and pathological conditions.  First, it was 
shown that the proposed microfluidic device could replicate physiologically relevant values of 
permeability down to the order of 0.1 µm/sec for the 10 nm Dextran macromolecules. Then, it 




using two clinically relevant agents, Mannitol and Lexiscan. To the best of our knowledge, this is 
the first time that Lexiscan have been tested on a microfluidic platform. Finally, it was observed 
that soft discoidal polymeric nanoconstructs could more efficiently adhere to the vascular walls 
under pathological vascular conditions than their rigid counterparts. Collectively, these results 
demonstrated that the proposed double-channel microfluidic device could be efficiently and 














Efficacy of molecular and nano-therapies 




The preclinical screening of new therapies still relies on simplified, two dimensional (2D) in vitro 
models that cannot replicate the biochemical and biophysical complexity of the human 
diseases.[121, 122] Three-dimensional (3D) cell assembly, such as cancer spheroids and 
organoids, provide authentic representation of the in vivo tissue organization but cannot reproduce 
some dynamic mass transport processes. These processes are crucial for different therapies as they 
regulate the intra-tissue accumulation of systemically delivered therapeutic agents, the diffusion 
of nutrients, chemokines and cytokines, as well as the migration and spatial re-arrangement of 
malignant and healthy cells.[123-125] Microfluidic devices emerged as more accurate tool for 
screening novel therapies in cancer and other diseases because can replicate both the 3D tissue 
organization as well as mimic the delivery of therapeutic agents or cell migration, thus offering a 
more accurate tool for screening novel therapies in cancer and other diseases [126-131]. With this 
objective in mind, microfluidic devices have been designed to model a variety of disorders, 




barriers, such as those arising at the interfaces between the blood vasculature and the brain tissue 
(blood brain barrier), the intestine (intestinal mucosal barrier) and the pulmonary alveoli (alveolar 
capillary barrier).  
 
In general, microfluidic devices for disease modeling can be realized with one, two or multiple 
compartments to replicate the architectural complexity of the native tissue and include 
tissue/vascular and tissue/tissue biological barriers. The single compartment configuration, 
typically, comprises of one channel that is filled by a natural hydrogel carrying the cells of interest. 
The therapeutic agents are administered through one inlet port and slowly diffuse towards the 
opposite outlet. These microfluidic devices have been extensively used to test the vascular 
transport and adhesion of macrophages[132-134], cancer cells[135-137], and nanoparticles[98, 
138-141] under diverse disease conditions. The two- and multi-compartment configurations 
comprise of multiple channels to separate out different tissue districts and more accurately 
replicate biological interfaces and barriers. In two-compartment configurations, one channel acts 
as the extravascular compartment (tissue), which is filled by a natural hydrogel carrying the cells 
of interest, while the second channel acts as the vascular compartment (blood vessel), which is 
continuously perfused by cell culture medium. The therapeutic agents are infused through the 
vascular compartment to simulate systemic administrations or through the extravascular 
compartment to model direct intra-tissue injections. Thus, the two-compartment configuration 
replicates a single biological interface, either a vascular/tissue or a tissue/tissue interface [142-
146].  Multi-compartment based microfluidic devices comprise of more than two channels with 
different architectures to replicate a variety of biological interfaces.[130, 147-150] The two and 




Selecting out a few notable examples from the literature, the group of Huh realized a two-
compartment device comprising of an upper channel, reproducing the ductal lumen with pre-
assembled breast carcinoma spheroids, and a lower channel, perfused by cell culture media to 
replicate the breast microvaculature.[143] A thin natural membrane with a layer of stromal cells 
was interposed between the two compartments. The system was validated by quantifying the anti-
proliferative effect of paclitaxel on breast cancer cells. Compartmentalized microfluidic systems 
were also used by Kamm and collaborators [147, 151, 152], and other authors[95] [153] to study 
the vascular dynamics of circulating cancer cells and their extravasation/intravasation potential. 
Previous work from Decuzzi group used a two-compartment microfluidic device to quantify the 
metastatic potential of breast cancer cells under different environmental conditions, including the 
use of inflammatory factors as chemo-attractants.[95] Other authors used multi-compartment 
systems to model the complex biological features regulating the selective operation of the blood 
brain barrier or the alveolar capillary barrier.[128, 154, 155] Habibovic and Reis groups described 
a “tumor-on-a-chip" model for assessment of gemcitabine-loaded nanoparticle efficacy on 
colorectal cancer.[144] The viability studies together with live imaging demonstrated a dose 
dependent effect of gemcitabine loaded nanoparticles to colorectal cancer cells (HCT-116) 
embedded in Matrigel© inside the microfluidic chip.[144]  
 
Herein, single- and double-channel microfluidic devices were employed for in vitro testing of 
model and innovative therapeutic compounds. In the single-channel device, a 3D tumor model 
simulated the direct injection/application of chemotherapy at the tumor site (i.e. in situ). In double-
channel microfluidic chip, in which the two parallel channels are connected by micropillars, - a 




chemotherapy. Glioblastoma multiforme (GBM) cancer was selected among numerous 
pathologies because it is referred as the most aggressive and lethal brain tumor in adults.[156] 
Previously, free docetaxel (DTXL) and spherical polymeric nanocontructs (SPN) loaded with 
DTXL (DTXL-SPN) were investigated for the treatment of cancer cells in conventional (2D) 
cultures and in vivo.[157-160] DTXL lacks specificity towards tumor cells and triggers huge side 
effects on patients.[161, 162] Its severe systemic toxicity together with its low solubility, leads to 
short blood circulation time in the body, erratic absorption patterns and thus, requires frequent 
administrations [163] ideally at the tumor site. Notwithstanding, a new promising selective 
chemotherapeutic, N-(fluorenylmethoxycarbonyl)-glucosamine-6-phosphate (Fmoc-Glc6P), has 
demonstrated a potent anti-cancer efficacy on osteosarcoma and breast cancer cells.[164-166] In 
this work, the efficacy of several therapeutic agents such as free DTXL, nanoparticles loaded with 
DTXL (DTXL-SPN), and Fmoc-Glc6P was tested for comparative purposes.[164-166]  
 
3.2 Materials and Methods 
3.2.1 Fabrication and Characterization of the Microfluidic Chips 
Two different microfluidic chip designs were employed in this study: a single and double channel 
chip, described in detail by Manneschi et al. [145]. Briefly, a single channel silicon master template 
was obtained from a negative template of SU8-50 photoresist. The silicon template was replicated 
using a mixture of polydimethylsiloxane (PDMS) Sylgard 182 from Corning (Italy) by mixing 
base and curing agent in a ratio 1:10 (w/w). The PDMS solution was casted on the silicon template, 




cleaned with a scotch-tape and inlet and outlet ports were created with a biopsy punch.  Oxygen 
(O2) plasma treatment (pressure = 1.0 mbar, power = 20 W, time = 20 s) was performed and PDMS 
replicas were bonded to the glass coversheets. This chip had a length of 27 mm, a height of 42 µm 
and a width of 210 µm. For the fabrication of the double channel chips, an optical mask of glass 
was used together with a two lithographic steps to pattern  first the micropillars and then the double 
channels into the silicon master chip. The obtained silicon master template was then replicated via 
soft lithography, as reported previously. The final PDMS template was composed by two 
microfluidic channels with a length of 27 mm, interconnected in the middle part by an array of 
micropillars with 500 µm in length with a gap size of 3 µm. The two channels had a height of 50 
µm and a width of 200 µm. These chips had two parallel channels: the top channel corresponded 
to the vascular part where the treatment solutions (e.g. drugs, nanoparticles, and active compounds) 
were added; and the bottom channel corresponded to the extravascular part and contained a 
hydrogel with embedded cells to mimic the 3D structure of a tumor. Each channel had one inlet 
and one outlet and were connected by a permeable micropillar membrane.  
 
3.2.2 Scanning Electron Microscopy (SEM) 
 SEM images of microfluidic chips were obtained using the equipment JSM-6490LV, JEOL and 
Helios Nanolab 650, FEI Company. These images were acquired after curing the PDMS on the 
silicon master template and peeling of the PDMS replicas. The microfluidic chips were sputter-
coated with gold. Low-magnification and high-magnification SEM images were obtained with 





3.2.3 Culture of Human Glioblastoma Multiforme (U87-MG) Cells 
and Primary Human Astrocytes 
The cancer cells were previously transfected with GFP to easily visualize them in situ 
longitudinally with time. U87-MG GFP+ cells were cultured in Minimum Essential Medium Eagle 
(EMEM, Gibco, ThermoFisher Scientific) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) and 1% penicillin/streptomyocin (P/S). Human cortical astrocytes (#1800, ScienCell 
Research Laboratories, US) were cultured with astrocytes medium with 1% P/S. U87-MG GFP+ 
and human astrocytes were cultured in T150 flasks until confluence. After the trypsinization, human 
astrocytes were stained with Vybrant™ DiI Cell-Labeling Solution (#V22885, ThermoFisher 
Scientific), according to the manufacture's protocol. Then, the cells were washed 3 times with PBS 
(1X) to remove the excess dye. After proper optimization of matrix’s concentration and cell 
density, a concentration of 50:50 Matrigel©/cells in EMEM medium were prepared to a final 
number of 100,000 cells embedded in Matrigel© per chip (Corning). Single- or double channel chips 
were used to culture U87-MG GFP+ cells or astrocytes with Matrigel© for 24 hours to form a confluent 
3D cell network and after that different treatment solutions were added for 24, 48 and 72 hours. After 
each time point, the cell viability was analyzed by confocal microscopy.  
 
3.2.4 Human Glioblastoma Multiforme (U87-MG) Cells in static 
culture conditions 
Static cultures on 96-well plates (10,000 cells/ well) were performed with U87-MG cells for 24 
hours. After that, different treatment solutions (0.001, 0.01, 0.5, 0.1, 1 and 10 µM free DXTL and 




conducted after 24, 48 and 72 hours. Cellular metabolism in 2D monolayers was evaluated using 
MTT assay and following supplier’s instructions. U87 MG cells were seeded into a 96-well plate 
and after 24 hours, the cells were treated with different DTXL concentrations (0.001, 0.01, 0.5, 
0.1, 1 and 10 µM) and for upto 72 hours. These studies were performed by changing or without 
changing the DXTL solutions every day. The optical density (O.D.) was read at 490 nm on a 
multiwell microplate reader. Cell viability was calculated as the difference of optical density (O.D) 
values obtained for the controls (cell-seeded conditions without treatment) and the O.D. measured 
values of the cell-seeded conditions treated with different DTXL concentrations assessed after 24, 
48 and 72 hours. These values were then converted in % of viable cells. The half-maximal (50%) 
inhibitory concentration (IC50) was estimated as the 50% of cell viability relative to the negative 
control of cell death (cells grown in TCPS – without treatment, only EMEM medium). 
The DNA concentration of the cell lysates was quantified by using the Quan-iTTM PicoGreen® 
dsDNA assay kit (Molecular Probes/Invitrogen) following the manufacturer’s instructions.  
 
3.2.5 Treatment Conditions using Single and Double Channel 
Microfluidic Chips 
Microfluidic chips were sterilized in an autoclave at 120°C. Then, the channels were aspirated 
within the biohood and the chips were left inside the incubator overnight to remove the water from 
the channels. U87-MG GFP+ cells or human astrocytes embedded in Matrigel were injected into 
microfluidic chips and were cultured for 24 hours to form a 3D brain tumor-like tissue. 
Single channel microfluidics chips were used to screen several concentrations of DTXL.A stock 




with EMEM to 0, 0.01, 0.5, 0.1, 1 and 10 µM solutions. To assess the cytotoxicity of the anti-
cancer drug DTXL, EMEM with different drug concentrations (0.01, 0.5, 0.1, 1 and 10 µM) was 
added to the channel inlet and left to diffuse across the 3D brain tumor-like tissue. The therapeutic 
solution was added every single day to the chip, for upto 72 hours. EMEM was used as a control 
in this set of experiments. 
In the double-channel microfluidic device, three different treatments were investigated: (1) free 
DTXL (0.01, 0.1, and 10 µM); (2) spherical nanoconstructs (SPNs) loaded with DTXL (10 µM) 
(DTXL-SPN); and (3) 500 µM free N-(fluorenylmethoxycarbonyl)-glucosamine-6-phosphate 
(Fmoc-Glc6P). All solutions were prepared in EMEM. The DTXL-SPN were fabricated as 
previously described by us.[160] Fmoc-Glc6P compound was synthesized following the procedure 
described by Pires et al.[164] The different therapeutics or just EMEM medium (control) were 
injected into the vascular (top) channel every day. After 24, 48 and 72 hours, each (bottom) channel 
with U87-MG GFP + cells embedded in Matrigel was observed using the confocal microscope. 
 
3.2.6 Confocal Microscopy Analysis 
Confocal fluorescent microscopy (Nikon A1R+/A1+; objectives Nikon, 10X or 20X) has been 
extensively used to document the 3D organization of U87-MG GFP+ cells or human astrocytes 
embedded in Matrigel throughout the microfluidic chips as well as its viability over time. After 
each time period, single and double channel microfluidic chips cultured with U87-MG GFP + cells 
and human astrocytes stained with Dil and embedded in Matrigel were observed and analyzed 
using a confocal laser microscope where  a z-stack throughout the height of the channels was 




Each experiment involved at least five chips per condition and was repeated three times. The same 
region of interest (ROI) was analyzed after each time point. High-resolution Z-stack images were 
processed for 3D reconstruction and measurement of fluorescence intensity were performed using 
NIS-Elements AR (Nikon) software. Cell viability, with EMEM only (control) and after different 
treatments, was determined measuring the mean fluorescence intensity exhibited by green 
fluorescent protein (GFP+) cells. Cell viability was presented as percentage, calculated from the 
fluorescence intensity after 24, 48 and 72 hours. The half-maximal (50%) inhibitory concentration 
(IC50) was estimated as the 50% of cell viability relative to the negative control of cell death (cells 
grown in 2D monolayers in TCPS). Also, for the estimation of IC50 of increasing concentrations 
of DTXL on cells cultured in 2D and in single channel microfluidic chips at 24, 48 and 72 hours, 
a study for the best regression models that would fit the curvature of the data obtained was 
performed. A logarithmic curve was considered as the best fitting (nonlinear regression) and the 
IC50 for each time point of both experiments was estimated. 
 
3.2.7 Statistical Analysis 
Data are expressed as mean ± standard deviation. Single factor analysis of variance (ANOVA) was 
used to determine statistical significance within a data set. If ANOVA detected a significant 
difference within the data set, Tukey’s honestly significantly different (HSD) multiple comparison 







Two different microfluidic device configurations were used to reproduce in vitro the complex 3D 
organization of cancer cells: a single-channel (Figure 3.1A) and a double-channel (Figure 3.1B) 
configurations. The first device comprised of a channel with a total length of 27 mm and a 
rectangular cross section of 210 m (width) by 42 m (height). The second device comprised of 
two parallel channels with a total length of 27 mm and a rectangular cross section of 200 m 
(width) by 50 m (height). In the center of the double-channel device, the two channels were 
connected through a series of micropillars over a length of 500 m (Figure 3.1B, bottom-right 
inset). The micropillars realized a membrane with openings of about 3 m in size.    
Figure 3.1. Microfluidic devices. A) Schematic representation of the single-channel device, including a scanning 
electron microscopy (SEM) micrograph of the channel and a confocal image of U87-MG GFP+ cells cultured in 
Matrigel matrix. B)  Schematic representation of a double-channel device, including a SEM micrograph of the 
two-channels (extravascular and vascular compartments). The bottom-right inset gives a SEM image of the 
micropillars realizing the permeable membrane between the two-compartments. (Scale bar: 100 µm, except for 




Within these devices, 3D-like tumor tissues were realized using green-fluorescent protein 
transfected (GFP+) human glioblastoma multiforme cancer cells (U87-MG) embedded in a 
Matrigel matrix. In the single-channel configuration (Figure 3.1A), the U87-MG embedded in 
Matrigel was deposited along the channel length. This configuration mimiced an in situ 
administration of chemotherapeutic agents at the tumor site, similar to a conventional organoid or 
tumor spheroid, where nutrients, chemokines and therapeutic agents diffuse across the malignant 
mass following concentration gradients. In the double-channel configuration, simulating the 
systemic administration treatment (Figure 3.1B), the matrix with the cancer cells was deposited 
in the extravascular channel – cancer tissue – whereas the second channel was traversed by 
medium – emulating blood flow. The series of micropillars served to realize the blood/tissue 
interface that confines the Matrigel matrix on the extravascular compartment while supporting the 
extravasation of nutrients, molecules and nanoparticles. Here it is important to note that, typically, 
the biological barriers in the largest majority of microfluidic devices are realized by placing in 
between two adjacent channels or compartments pre-fabricated porous membranes  to locally 
reproduce a Boyden chamber. Consequently, the two compartments lay on different focal planes 
and cannot be imaged simultaneously under a microscope. Differently, the compartments in the 
present microfluidic device lay horizontally on the same focal plane.[95, 145]  
 
Different therapeutic agents (Figure 3.2), including free docetaxel (DTXL), DTXL-SPN, and the 
free aromatic N-glucoside Fmoc-Glc6P, were infused in the microfluidic device to assess their 
cytotoxic potential on cancer cells under different conditions. The very potent anti-cancer drug 




already published by the authors.[160] Similarly, the Fmoc-Glc6P compound was synthesized 
based on the work of Pires et al. [164].  
 
In the single-channel configuration, the therapeutic agents were slowly infused through an inlet 
port and allowed to diffuse across the whole tumor matrix to reach the outlet port. In the double-
channel configuration, the therapeutic agents are slowly infused in the blood channel and perfuse 
into the extravascular compartments by crossing the micropillar membrane.  
Figure 3.2. Therapeutic agents. A) Chemical structure of docetaxel (DTXL). B) Schematic representation of the 
spherical polymeric nanoparticles (SPN) composed by 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-
Poly(ethylene glycol) (DSPE- PEG), Lipid-Rhodamine as a fluorofore, dipalmitoylphosphatidylcholine (DPPC), 
poly(lactic-co-glycolic acid) (PLGA), and loaded with docetaxel (DTXL-SPN); diameter and Z-Potential, size 
distribution measured by Dynamic Light scattering (DLS), the release profile at 37 °C in physiological solution (PBS, 
pH 7.4);  and (C) 500 µM Fmoc-Glc6P for 24, 48 and 72 hours. C) Chemical structure of the aromatic N-glucoside 





3.3.1 Assessing the cytotoxic potential of therapeutic agents in the 
single-channel microfluidic device 
In the single-channel configuration (Figure 3.1A), 3D tumor-like tissues were obtained using U87-
MG GFP+ embedded in a Matrigel matrix and then the different therapeutics were injected directly 
throughout the 3D structure. The cancer cells were transfected with GFP to easily visualize them 
in situ longitudinally with time. A sufficiently large number of cells (100,000) were mixed with 
Matrigel to realize a confluent tridimensional cell network (Figure 3.1A and 3.3A-E, time 0 hours 
– without DTXL). To assess the cytotoxic potential of the anti-cancer drug docetaxel (DTXL), 
medium with different drug concentrations (0.01, 0.5, 0.1, 1 and 10 µM) was added to the channel 
inlet and left to diffuse across the 3D tumor-like tissue. The therapeutic solution was added every 
single day into the chip, for upto 72 hours. The viability of the tumor cells was estimated by 
analyzing the variation of the green fluorescent intensity over time: an increase in fluorescence 
intensity was associated with a higher cell density, thus indicating cell viability; whereas a decrease 
in fluorescence intensity was associated with a lower cell density, thus indicating cell death.  
The fluorescent images of Figure 3.3A-E report the variation in cancer cell density within a 
representative section of the channel ( 2.9 mm) over time (from 0 to 72 hours) and for different 
DTXL concentrations. As expected, the cell viability reduced upon DTXL administration in a 
time- and concentration-dependent fashion. At the lowest concentration of DTXL (0.01 µM), the 
cell density started to decrease significantly only after 72 hours (Figure 3.3A). On the other hand, 
the cell density was already dramatically reduced after the first 24 hours at the highest tested 
concentrations of 1 and 10 µM (Figure 3.3D, E). The cell viability percentage for all the different 
treatment conditions and time points  presented in Figure 3.3F and quantitatively documented the 





Figure 3.3. Human brain tumor cell viability analysis in single-channel microfluidic device– free DTXL. A-E) 
Representative confocal fluorescent microscopy images of U87-MG GFP+ cells cultured in Matrigel and exposed to 
different doses of free DTXL (0.01, 0.05, 0.1, 1 and 10 µM) at different time points (24, 48 and 72 hours). The scale 
bar is 50 µm and applies to all images. F) Cell viability analyses and IC50 values determined for the different time 
points. Results are expressed as mean ± SD (n = 5 per time point). All concentrations presented a significant difference 
over time compared to control (no treatment) except at 0.01 µM after 24 and 48h hours. *: p < 0.01 and ** p < 0.05 





estimated for each different time point returning the values 0.0830 ± 0.0043, 0.0267 ± 0.0013 and 
0.0020 ± 0.0005 µM  µM at 24, 28, and 72 hours, respectively.  
 
The cytotoxic effect of free DTXL was also tested on U87-MG GFP+ cell monolayers cultured in 
a conventional 96 well-plate system. In this case, the cell viability was assessed via a standard 
MTT assay (Figure 3.4) with and without changing the DTXL solution every day. In the first case, 
when the drug solution was changed daily, the measured IC50 values were 1.1822 at ± 0.0025 at 48 
hours and 0.1083 ± 0.0008 µM at 72 hours. At the 24 hours time point, cell viability was well 
above 50% even at the highest tested concentration of 10 M. A similar trend was observed at all 
time points when the DTXL solution was not changed for the full duration of the experiment. This 
observation would imply that DTXL had a higher cytotoxic potential on 3D cells as compared to 
2D cell monolayers. 
Figure 3.4. Metabolic activity of U87-MG.  Cells cultured in 96-weell plates treated with increasing concentrations 
of free DTXL (0.01, 0.5, 0.1, 1 and 10 µM) changing (B) and without changing (A) DTXL solutions every day. Data 
are shown for culture of 10,000 cells per well as optical density (O.D.) values from MTT assay at 24, 48 and 72 h time 
points. Results are expressed as mean ± SD (n = 5 per time point).  These values were then converted in % of viable 
cells. (*) Indicates a significant difference (p < 0.01) compared with the control (cells cultured without treatment); (#) 




3.3.2 Assessing the cytotoxic potential of therapeutic agents in a 
double-channel microfluidic device 
 Based on the data obtained for single-channel device, the cytotoxic potential of DTXL was 
examined only for the highest concentrations of 0.01, 0.1 and 10 µM. The therapeutic agents were 
slowly infused into the vascular compartment (upper channel) (Figure 3.1B) and transported 
partially to the extravascular compartment (bottom channel – cancer tissue compartment), filled 
with the Matrigel matrix and  U87-MG GFP+ cells, leading directly to the chip outlet. In other 
words, as per the systemic administration of any compound, part of the injected dose does reach 
the diseased tissue (in this case the extravascular compartment) whereas the remaining portion is 
distributed throughout the body (here the outlet port in the chip).  
 
In this double-channel configuration, three therapeutic agents were tested, namely free DTXL 
(0.01, 0.1 and 10 µM); DXTL-SPN (10 µM of DTXL); and the free compound Fmoc-Glc6P (500 
µM). The viability of the U87-MG GFP+ cells were assessed at 24, 48 and 72 hours, following the 
variation in green fluorescence intensity as described above.  
For free DTXL, no cytotoxic effect was observed at 0.01 µM DXTL for all tested time points 
(Figure 3.5A). At 0.1 µM DXTL, a significant cell death was detected only at 72 hours (Figure 
3.5B). At the highest tested concentration of 10 µM, free DXTL induced cell death in a time 
dependent fashion (Figures 3.5C). Quantitative data for the cell viability are presented in Figure 
3.5D. Notably, in the double-channel microfluidic device, the cell viability was generally higher 
than 50% for the tested drug concentrations except in the case of 10 µM DTXL at 72 hours. As 
such, IC50 values could not be estimated within the considered range studied. Reconstructed 3D 




the 10 µM free DXTL treatment. These documented the progressive reduction in fluorescence 
intensity (cell death) moving from time 0 hours, when the extravascular compartment appears all 
green against a black vascular compartment, to 72 hours, when only a few sparse cell assemblies 
are still visible (Figure 3.5E). It was noticed that at the given drug concentrations, the cytotoxic 
activity of DTXL on the U87-MG cells was significantly reduced in the double-channel 
microfluidic device as compared to the single-channel configuration. Indeed, this should be 
ascribed to the diminished concentration of DTXL reaching the tumor compartment as part of the 
infused drug was washed away via the blood compartment.  
Figure 3.5. Human brain tumor cell viability analysis in double-channel microfluidic device – free DTXL. A-
C) Representative confocal fluorescent microscopy images of GFP+ U87-MG cells cultured in Matrigel and exposed 
to different doses of free DTXL (0.1, 1 and 10 µM) at different time points (24, 48 and 72 hours). D) Cell viability 
analyses determined for the different culturing conditions. E) 3D-Reconstruction of confocal fluorescent images 
showing the GFP+ U87-MG cell density at different time points post exposure to 10 µM DTXL. (Scale bar: 100 µm. 




Differently, in the single-channel configuration, all the infused DTXL was distributed within the 
tumor tissue and affected the viability of the cancer cells. Also this is a fundamental difference 
between the double-channel microfluidic device and the cancer spheroids and organoids.  
  
For assessing the cytotoxic potential of DTXL-SPN, only the highest DTXL dose was considered 
(10 M). The confocal microscopy images of Figure 3.6A show a progressive reduction in green 
fluorescence intensity over time that was associated with cell death.  
At all considered time points, the cell viability for the DTXL-SPN (Figure 3.6B) was comparable 
to that quantified with free DTXL (Figure 3.5D).  
Figure 3.6. Human brain tumor cell viability analysis in double-channel microfluidic device – DTXL-SPN. A) 
Representative confocal fluorescent microscopy images of U87-MG GFP+ cells cultured in Matrigel and exposed to 
SPN loaded with 10 µM DTXL (DTXL-SPN), at different time points (24, 48 and 72 hours). B) Cell viability analyses 
determined for the different culturing conditions. Results are expressed as mean ± SD (n = 4 per time point). *: p < 
0.01 compared with the control (no treatment).  C) Representative confocal fluorescent microscopy images at 72 hours 




Specifically, at 24 hours, the cell viability was 69 ± 30% for DTXL-SPN vs 80 ± 6% for free 
DTXL. This reduced to 64 ± 12% vs 57 ± 2% at 48 hours and to 56 ± 17% vs 40 ± 1% at 72 hours 
for DTXL-SPN and free DTXL, respectively.  
 
By using spherical polymeric nanoparticles SPN labeled with the red fluorescent dye Rhodamine-
B (RhB-SPN), it was demonstrated that the infused nanoparticles were able to permeate across the 
micropillar membrane and diffuse throughout the tumor-like tissue (Figure 3.6). The red dots 
(Figure 3.6C – left) was associated with the RhB-SPN only and the tumor cells appeared green 
(Figure 3.6C – center). The right insets of Figure 3.6C shows the overlap between the red and 
green channels demonstrating the co-localization of the nanoparticles with the cancer cells. As 
expected, the nanoparticle density was particularly high in the vicinity of the permeable micropillar 
barrier and reduced upon moving deeper into the extravascular compartment. It should be noticed 
that even in the case of the DTXL-SPN, a significant dose of nanoparticles and DTXL was 
expected to be washed away and lost without ever reaching the malignant tissue similar to the 
situation in vivo.   
Interestingly, in the case of DTXL-SPN treatment, a significant asymmetric distribution for dead 
versus live cancer cells were observed. Figure 3.6A shows that live U87-MG cells (green 
fluorescent) were more abundant on the right-hand side of the channel, with respect to the 
micropillar permeable barrier. Also, the flow in the blood compartment was directed from right to 
left. This would indicate that the DTXL-SPN permeation and distribution within the extracellular 
matrix was governed by advection in addition to diffusion. This also appeared in Figure 3.6C 
where the RhB-SPN accumulation was higher on the left-hand side of the channel with respect to 




compounds for which advection is in general negligible. Importantly, this process can only be 
observed is the actual vascular transport of therapeutic agents towards the diseased tissue is 
modeled.  
 
Finally, the double-channel microfluidic device was also used to assess the therapeutic efficacy of 
a novel  compound – Fmoc-Glc6P for this type of cancer cells. The efficacy of this compound was 
originally demonstrated on osteosarcoma (SaOs-2) and breast cancer (MDA-MB-468) cell 
lines.[165] It acts as an efficient cancer antimetabolite by concomitantly blocking the glucose 
transporter 1 (GLUT1) via specific interactions and formation of a nanonet serving as a physical 
barrier between the cancer cells and their environment.[165, 166] The treatment was more efficient 
in spheroids  compared to  2D culture due to the higher GLUT1 expression in 3D cultures.[164-
166] Notably, GLUT1 was significantly upregulated both in vitro and in vivo GBM and thus, we 
hypothesized that this therapeutic molecule  could also be efficient in GBM.[167, 168] Indeed, 
Fmoc-Glc6P demonstrated a strong anti-proliferative and cytotoxic effect on U87-MG cells 
cultured in 2D as well as in the double-channel microfluidic chips. We selected a concentration of 
500 M for our experiments based on the previous studies with Fmoc-Glc6P.[164].  
 
Similar to the other therapeutic agents, Fmoc-Glc6P was infused directly into the vascular 
compartment. A significant drop in cell survival was observed over time (Figure 3.7A). At 72 
hours only a few sparsely viable U87-MG cells were  visible in the channel. This was  
precisely quantified in Figure 3.7B with a U87-MG cells showed viability equal to 46.54 ± 




was also documented by measuring the cell proliferation rates using the Quan-iTTM PicoGreen® 
dsDNA assay kit (Figure 3.8). 
 
 
The DNA assay showed a significant decrease (p < 0.01) in cell proliferation over time in the 
presence of 500 M Fmoc-Glc6P. As expected, this was more effective than a 10 M free DTXL 
in controlling the proliferation rates. Furthermore, the possible cytotoxic effects of Fmoc-Glc6P 
Figure 3.7. Human brain tumor cell and astrocytes viability analysis in double-channel microfluidic 
device – Fmoc-Glc6P. A) Representative confocal fluorescent microscopy images of U87-MG GFP+ cells 
cultured in Matrigel and exposed to 500 µM of Fmoc-Glc6P, at different time points (24, 48 and 72 hours). B) 
Representative confocal fluorescent microscopy images of astrocytes stained with Dil, cultured in Matrigel and 
exposed to 500 µM of Fmoc-Glc6P, at different time points (24, 48 and 72 hours). C,D) Cell viability analyses 
determined for the different culturing conditions of the U87-MG cells GFP+ and human astrocytes stained with 
Dil. Results are expressed as mean ± SD (n = 4 per time point). *: p < 0.01 compared with the control (only 




compound on healthy brain cells – human astrocytes – was assessed within the same microfluidic 
device (Figures 3.7C). The astrocytes were stained with the red fluorescein molecule Dil and their 
viability was assessed.. Fmoc-Glc6P clearly show no toxic effect on human astrocytes (Figures 
3.7C and Figure 3.7D) with no decrease in cell viability over time. This result would indicate the 





Figure 3.8. DNA concentration of U87 MG cells cultured in 96-well plates using different treatments. The 
therapeutic solutions consisted in: 0.5 mM Fmoc-Glc6P compound and different concentrations of free DTXL 
(0.001, 0.01, 0.5, 0.1, 1 and 10 µM) for 24, 48 and 72 hours.  (*) Indicates a significant difference (p < 0.01) or 
(**) (p < 0.05) compared with the control (cells cultured without treatment); (#) a significant differe 





3.4 Discussion and Conclusions 
Conventional cell culture monolayers poorly recapitulate the native physiology of the diseased 
tissue  since they do not support complex 3Dcell organization and the dynamic arrangement under 
multiple, different physiological clues. On the other hand, microfluidic chips allow  to simulate 
complex cell-culture microenvironments, including the realization of vascular-tissue and tissue-
tissue interfaces, with spatiotemporal chemical gradients and mechanical clues of living tissues. 
This enables the development of new in vitro disease models and potentially the replacement of 
animal experiments [131, 169]. Indeed, microfluidic devices tend to overcome several limitations 
of the current animal models, including cost, labor time, reproducibility, insufficient similarity 
with the human physiology and undesired immune responses and indeed ethical issues. Studies 
have also suggested that the use of microfluidic devices might accelerate the design of drug-
administration regimens for phase I clinical trials [129].  
In this work, microfluidic devices with a single-channel and double-channel configurations were 
considered to emulate the administration of chemotherapy for brain tumor treatment in situ and 
systemically, respectively. Human U87-MG cells were dispersed into a Matrigel matrix, deposited 
within the channel of the microfluidic device and exposed to a therapeutic solution containing  free 
docetaxel (DTXL), docetaxel loaded nanoparticles (DTXL-SPN) or the molecular compound 
Fmoc-Glc6P. In the double-channel microfluidic device, the solution with the therapeutic agent 
was infused in the so-called blood compartment  while the tri-dimensional tumor-like tissue was 
deposited in the other channel (extravascular compartment). In both devices, the cancer cell 
viability was assessed by quantifying the intensity of the green fluorescence associated with the 




By comparing the brain cancer cell viability in the tumor chip (single-channel microfluidic device) 
with a conventional cell monolayer, it resulted that U87-MG cells were more susceptible to DTXL 
chemotherapy when they were arranged in a 3D matrix as documented by a 50 times decrease in 
the characteristic IC50 values. Free DTXL showed greater toxicity for U87-MG cells cultured into 
single-channel microfluidic devices compared to those cultured in conventional 2D monolayers. 
This confirmed the potential of free DTXL to be injected in situ at the tumor site. This trend of 
high chemosensitivity exhibited in 3D models was previously described in a study using 
bevacizumab. It was showen that when it was added to standard chemoradiation in phase III 
clinical trials it exhibited marked radiosensitizing activity in the developed 3D model of GBM but 
had no effect on 2D cells[170]. Moreover, a study investigating different cell lines from patients 
with head and neck squamous cell carcinoma revealed that LK0902 cells were more sensitive to 
cetuximab treatment in 3D conditions than cells grown in 2D[171]. Finally, this finding was also 
corroborated by Brito et al.[166] where they observed that the efficiency of the treatment with 
Fmoc-Glc6P was higher in spheroids as compared to the conventional 2D cultures due to higher 
expression of glucose transporter 1 (GLUT1) by the cancer cells.[166]  
Blood-tumor models (double-channel microfluidic device) could also replicate flow dynamics and 
the actual vascular transport of systemically administered therapeutic agents. By comparing the 
brain cancer cell viability for the single versus the double-channel configuration, it was concluded 
that significant amounts of therapeutic agents were lost in the circulation and distributed to other 
tissue districts without ever reaching the malignant cells. This resulted in a dramatic drop in cell 
viability for the same given administered dose in the double- vs the single-channel configuration. 
Also, moving from small molecules, such as docetaxel, to larger therapeutic agents, such as 




distribution and, therefore increased efficacy. This was documented by the asymmetric distribution 
of live vs dead tumor cells which was positively correlated with the vascular flow direction. It was 
also shown that DTXL-loaded nanoparticles were more efficient than the free DTXL molecules in 
inducing cell death. Additionally, free DXTL and DTXL-SPNs were less efficient than Fmoc-
Glc6P to induce U87-MG cell death when cultured into double-channel microfluidic device. 
Moreover, Fmoc-Glc6P targeted specifically U87-MG cells without any deleterious effect in 
human astrocytes. These findings demonstrated that the double-channel can better replicate the 
vascular transport of systemically administered therapeutic agents and recreates closely the in vivo-
like environment than 2D or the single-channel configuration. Also, Fmoc-Glc6P demonstrated 
high potential to be applied systemically because it acted specifically against cancer cells without 
causing adverse effects on healthy cells, combining a greater therapeutic efficacy with minor side 
effects. 
 
Several chemotherapeutics, namely free DTXL, DTXL-SPN and Fmoc-Glc6P, were investigated 
using microfluidic chips. To elucidate the behavior and assess their anti-cancer therapeutic efficacy 
in a more realistic scenario, we used single- and double-channel microfluidic devices simulating 
in situ and systemic administration, respectively. Importantly, the U87-MG cells cultured in 2D 
conditions were clearly more resistant to DTXL treatment, presenting IC50 50-fold greater, as compared 
to those cultured in single-channel microfluidic chips. This study also clearly demonstrated the 
outstanding behavior of Fmoc-Glc6P, showing a selective effect on cells inducing the death of 
GBM cancer cells, without eliciting deleterious effect on healthy/normal cells. Also, the effect of 
Fmoc-Glc6P, specifically on cancer cells cultured into double-channel microfluidic chips, showed 




Overall, this study demonstrated the importance of microfluidic devices as excellent predictive 
tool for modeling the in situ and systemic administration conditions of chemotherapeutics, to 
simulate the in vivo microenvironment of a tumor, reproducing complex spatial cell organization 
and mass transport processes and to assess the efficacy of new effective molecular- and nano-














 Three-dimensional extracellular layer 
mediated neural stem cell differentiation in a 
microfluidic device 
 
The Central Nervous System (CNS) is comprised of neurons, the primary functional units and glial 
cells, the supporting cells. These cells originate from a unique class of progenitor cells, called 
neural stem cells (NSCs), through a process known as neurogenesis. [172] NSCs are very attractive 
for regeneration therapy in the nervous system. They hold an immense promise for regenerative 
therapy of neurological diseases, such as Parkinson’s disease, Alzheimer’s disease, spinal cord 
injury and gene delivery systems for brain tumor treatments. [173] Self-renewal of NSCs is 
modulated by the so-called NSCs niche, composed of cellular and acellular components. Besides 
the critical role of growth factors and hormones, the extracellular matrix (ECM) that supports the 
developing neural cells plays a fundamental role in cellular differentiation. [174, 175] Maintenance 
of stemness of stem cells and efficient differentiation are often difficult to manipulate, making it 
necessary to  understand the relevant factors associated with NSCs proliferation and differentiation 
in vitro. Researchers have begun to use either ECM such as Matrigel© or individual ECM 
components such as collagen, laminin or fibronectin for in vitro neural differentiation experiments. 
[176, 177] Unfortunately, traditional NSCs cultures display several limitations. One major 
problem is the inability to precisely control the behavior of NSCs in culture. For example, precise 




traditional cultures, since they require relatively large volumes of media and correspondingly large 
amounts of costly growth factors and other reagents.[178] Microfluidic cell cultures offer the 
potential to overcome some of the limitations imposed by traditional culture tools. Moreover, 3D 
artificial microenvironments that mimic the in vivo microenvironments can be reconstructed for 
supporting the differentiation of NSCs. Several studies have characterized the physical, 
mechanical and biochemical cues for differentiation of NSCs by culturing these cells on micro-
patterned ECMs or nano-structured substrates. [179, 180]  
Here, as a proof of concept, a single-channel microfluidic system was presented for the 
differentiation of NSCs. The fully closed microfluidic device was designed to create in vivo like 
3D microenvironments for NSCs by varying the deposition of a tiny layer of Matrigel© onto 
microfluidic walls. For this purpose, microfluidic devices were fabricated with 
poly(dimethylsiloxane) (PDMS) by a conventional soft lithography process, as reported 
previously. [135] The channel was covered with basic components of the basal lamina and NSCs 
were cultured into the single-channel device under a continuous supply of medium over two weeks, 
as depicted in Figure 4.1. In this study, NSCs were freshly isolated from the hippocampus of 
embryonic rats and dissociated first by enzymatic digestion in Trypsin-EDTA 0.25% (20 min at 
37 °C) and subsequently by mechanical dissociation with a fine-tipped Pasteur pipette. The 
resulting tissue was resuspended in a Neurobasal medium supplemented with 2% B-27, 1% 
Glutamax-I, 1% Pen-Strep solution and 10% Fetal Bovine Serum. Afterward cells were plated 
onto a flask to form neurospheres. Neurospheres were checked under an optical microscope and 
ready to split when they reached 50-100um in diameters.. Afterward, neurospheres were collected 
from the flask, centrifuged, and resuspended in Accutase for gentle dissociation at 37°C by 




(+ 1% B27 + 1% P/S + 1% N2 + DMEM/F12 Glutamax + 20ng/ml EGF + 20ng/ml FGF) for 
seeding in microfluidic devices. 
 
Three types of ECM were tested for the  NSC culture in a single-channel microfluidic device based 
on different incubation time of Growth Factor Reduced (GFR) Matrigel© diluted 1:50 (vol/vol) 
with complete DMEM: 40 minutes incubation (3D_40), 1 hour incubation (3D_60) and 2 hours 
incubation at 37°C (3D_120) (Figure 4.2). The main component of Matrigel is laminin; so to 
confirm the formation of the extracellular layer, immunocytochemical staining of laminin was 
employed and confocal images were acquired. The GFR Matrigel© formulation was used to 
examine the effect of matrix component on the NSC differentiation, excluding the effect of growth 
factors from the original Matrigel© formulation. Matrigel© solution was allowed to gel in the 




microfluidic device, and then cells were flowed into the channel, allowing the attachment to the 
developed lamina.  
 
NSCs were cultured for 5 days in proliferation medium and from day 5 until day16 differentiation 
was induced by simply flowing differentiation medium (Neurobasal medium + B-27 + 1% P/S 
+1% Glutamax + 50ng/ml BDNF) into the microfluidic channel and the medium was changed 
everyday. In the first five days, attachment and proliferation of NSCs were evaluated by 
microscopy analysis (Figure 4.3). After five days, NSCs displayed a characteristic phenotype 
normally observed under differentiation conditions, suggesting a possible effect of extracellular 
Figure 4.2. Extracellular layer in single-channel microfluidic device. GFR Matrigel (1:50) was allowed to 
polymerize for 40 minutes (left image), 1 hour (center image), and 2 hour (right image), forming a tiny layer of basal 




layer component on NSCs differentiation. It was reported in several studies that laminin and 
laminin-enriched Matrigel© favored the differentiation of neural progenitor stem cells and neurite 
outgrowth. [181, 182] 
 
From day 5 the NSCs in microfluidic devices were cultured under a differentiation medium until 
day 16. At the end of the experiment, immunocytochemistry analysis was performed to evaluate 
the differentiation of NSCs, targeting the neural stem/progenitor marker Nestin and  β-tubulin III 
marker for mature neurons. As reported in Figure 4.4, NSCs in the microfluidic devices 
successfully differentiated into mature neurons. Laminin-enriched ECM was  employed to 
3D_40 3D_60 
3D_120 
Figure 4.3. Proliferation of NSC in microfluidic device at day5. NSCs were cultured for five days in 
proliferation medium and the effect of extracellular layer were evaluated by microscopic analysis. Scale bar 




differentiate NSCs in the microfluidic device [183], thus confirming the preliminary results 
obtained in this work.  
 
 
In this study, a microfluidic system was reported as an experimental platform for culturing and 
differentiation of NSCs under different 3D ECM stimuli. The system provided essential in vivo 
like cues for stimulating and guiding NSC differentiation, offering the possibility of fine-tuning 
the neural stem cell niche. Future studies will determine how the 3D microenvironment affects the 
NSC differentiation and will also consider the incorporation of other ECM components (for 
example hyaluronic acid) and the incorporation of various soluble factors co-culturing conditions 




Figure 4.4. NSCs differentiation in ECM layered microfluidic device. After 16 days of culture in 3D_60 
condition, NSCs differentiation was evaluated by staining of nestin (red) and beta-tubulin (green). Scale bar 






 Conclusion and Future Perspectives 
 
In this thesis, single-channel and double-channel microfluidic devices were presented to reproduce 
in vitro organ-on-chip. The first chapter consists of the literature review of the microfluidic 
evolution of new devices' production to mimic organs-on-chip. 
In the second chapter, a human microvessel-on-chip model was realized to reproduce 
macromolecules and polymeric nanoconstructs' vascular journey. To reproduce the human 
microvasculature, it was used the double-channel microfluidic chip. On one channel it was 
reproduced the vascular compartment, covered with endothelial cells, whereas on the second 
channel, it was reproduced the extracellular compartment, filled with a 3D matrix of collagen and 
Matrigel©. Endothelial cells formed a stable vascular barrier, replicating physiologically relevant 
values of permeability for small tracers and nanoparticles. It was demonstrated that vascular 
permeability could be modulated by specifically using Mannitol and Lexiscan as increasing 
permeability agents, resulting in permeability values 3-fold higher than basal value reported in 
physiological conditions . Also flow regime applied to the vascular barrier could be modulated 
from 0.2 dyne/cm2 to mimic tumor flow conditions to 0.7 dyne/cm2 to mimic physiological flow 
conditions. In this way, we recreated tumor-like conditions for testing the adhesion and 
margination of discoidal polymeric nanoconstructs with different mechanical stiffness. 




could be efficiently and effectively used to test the vascular behavior of a variety of drug delivery 
systems under various conditions. However, the proposed microfluidic device can be further 
optimized. First of all, human umbilical vein endothelial cells (HUVEC) are immortalized cell 
line, really easy to handle but with low resemblance of the human microvasculature and low 
expression of specific markers. For this reason, the next step is to consider the possibility to use 
primary endothelial cells or iPSC-derived endothelial cells to make the platform more similar to 
the in vivo physiology. Secondly, the extracellular compartment could be enriched with 
perivascular supportive cells, such as pericytes, smooth muscle cells and fibroblasts based on the 
vascular district's physiology that needs to be recapitulated.  
In the third chapter, a glioblastoma-on-chip was realized by using both the single-channel and the 
double-channel microfluidic chip. The single-channel device simulated the direct 
injection/application of chemotherapy at the tumor site (i.e. in situ). In contrast, the double-channel 
device simulated the systemic administration of chemotherapy. Several chemotherapeutics, 
namely free docetaxel (DTXL), DTXL-SPN and Fmoc-Glc6P, were investigated. The study 
demonstrated as the 3D microfluidic chip is a more realistic environment compared to the 2D 
conditions, since U87-MG cells were more susceptible to DTXL chemotherapy when they were 
arranged in a 3D matrix as documented by a 50 times decrease in the characteristic IC50 values.  
The 3D microfluidic condition reproduced complex cell-matrix organization and mass transport 
process that are essentials to test the effectiveness of anti-cancer treatment. It is also important to 
mention that, as a future step, it will be possible to combine the microvessel-on-chip previously 
reported here and the glioblastoma-on-chip. In this way, we could mimic a blood-brain-tumor 
barrier model. This model would allow refining techniques and strategies for nanomedicine or new 




Chapter four presented the single-channel microfluidic device as a suitable platform for the 
differentiation of neural stem cells (NSCs). NSCs were successfully cultured over 16 days, and the 
differentiation into mature neurons was confirmed. The microfluidic system provided extracellular 
stimuli to guide and support the proliferation and differentiation of neural stem cells. This last 
chapter was an embryonic project that could represent the basis for future research. In fact, the 
combination of the systems produced during this thesis could converge into realizing a blood-
brain-barrier model developed from the in situ differentiation of stem cells into the microfluidic 
devices.  
Although other experiments need to be performed, the double-channel microfluidic system opens 
the way to reproduce the neurovascular unit, closely resembling the in vivo interactions in 
physiological and pathological conditions, as in glioblastoma. The three studies reported in this 
thesis highlighted functional characteristics of single components of the neurovascular unit. The 
double-channel microfluidic system offer the possibility of define the vascular- and the neuro-
compartment, independently addressable but still ensuring the communication via direct and 
indirect contact. To this end, the first step  of this work addressed the permeability of endothelial 
cells only interfaced the extravascular compartment made of an hydrogel composed by specific 
components of the basal lamina and the extracellular matrix. Subsequently, single components of 
the basal lamina has been selectively deposited as a single layer into the extravascular 
compartment, in a more physiological approach. Neural stem cells have been cultured in order to 
study the differentiation of neural stem cells into the major players of the BBB, i.e. astrocytes and 
neural cells. Lastly, we analyze the accumulation and dosage of anti-cancer drugs into the glioma-
extravascular compartment. Future works will look at the combination of endothelial cells, neural 




conditions, endothelial cells are interfaced with differentiated neural and glia cells, lading in their 
own deposited matrix, resembling the formation and cell-cell and cell-matrix interactions 
characteristics of an healthy BBB. In pathophysiological conditions, as in glioblastoma, cross-talk 
between cancer cells and glia cells can promote aggressiveness of cancer cells and drug-resistance. 
Moreover, it is important to highlight that also the matrix can be selectively tuned in composition 
and stiffness. In fact, it is noted that in cancer conditions it is promoted also a stiffening of the 
extracellular matrix. This can be easily addressed in our system, getting light on the effect of the 
stiffness of the matrix on all involved players: primarly cancer cells, but also endothelial cells and 
the accessibility to anti-cancer treatments.  
With this new setup, it should be possible to gain a better insight into cell-cell and cell-matrix 
interactions and elucidate unknown mechanisms involved in stem cell differentiation, cell-cell 
crosstalk, and drug delivery. Most importantly, this microfluidic system will help minimize the 
gap between the in vitro and in vivo experiments, contributing to the reduction of animal 
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